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Introduction 
Before the presentation of the problem, it is very useful to remember that human body is made up 
of various organ systems such as: musculoskeletal system (bones and muscles), respiratory system 
(lungs), cardiovascular system (heart and blood vessels), gastrointestinal system, integumentary 
system (skin), nervous system (brain, spinal cord and nerves) and urinary system (kidneys, 
bladder). Each system is made up of individual organs that function together to ensure  that the 
total system works. Each organ is built up of tissues such as muscle, nerves, connective tissue, 
bone, epithelial tissue. Each individual tissue is made up of specific types of cells. The cell is the 
smallest building block of the body. The body is made up of billions of cells. The cell contains 
genetic material in its nucleus that determines the function and characteristics of the cell and 
therefore of the all body . The genetic material order the cell when to grow, divide and replicate. 
As cells age, they eventually die and are replaced by other cells that divide to replenish the aging 
cells. It may happen that an alteration occurs in a cell's genetic material or some other alteration 
occurs in the cell and it begins to grow, divide and replicate itself, uncontrollably. The body's 
immune system may detect this and destroy the abnormal cells. If the body does not detect this 
abnormality, then the cell continues to divide and form a tumor.[1] 
1.1. Bone tumor classification 
Tumors can be classified as benign or malignant. Depending upon the type of cell that the tumor is 
derived from, a malignant tumor can be classified as a sarcoma or a carcinoma. Malignant tumors 
can also be considered primary or secondary. In terms of bone tumors, a primary bone tumor 
arises directly from a particular bone. Secondary bone tumors are tumors that involve the bone 
but they originates from a cancer in another part of the body. Primary malignant bone tumors are 
sarcomas. Secondary bone tumors are called metastatic bone tumors or metastatic bone cancers 
and most are carcinomas that have traveled from other primary tumors such as breast cancer, 
lung cancer, prostate cancer, kidney cancer, thyroid cancer and gastrointestinal cancer. For 
instance, breast cancer that spreads to the bone; the breast cancer is the primary cancer and the 
breast cancer that is in the bone is a secondary cancer or a metastatic cancer.[1] 
In table 1.1 , there is a bone tumor classification divided in benign and malignant pathology. 
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Category Benign Malignant 
Osseous 
Osteoma 
Osteoid Osteoma 
Osteoblastoma 
Osteosarcoma 
 
Cartilaginous 
  
Enchondroma 
Osteochondroma 
Chondroblastoma 
Chondromyxofibroma 
 
Chondrosarcoma 
 
Fibrous 
 
Fibrous dysplasia 
Fibrocartilaginous 
Dysplasia Histiocytoma 
Osteofibrous Dysplasia 
Fibroma 
Benign Fibrous 
Desmoplastic Fibroma 
 
Fibrosarcoma 
Malignant Fibrous 
Histiocytoma 
 
 
Small Round 
Blue Cell 
 
Eosinophilic Granuloma 
Infection 
Ewing’s Sarcoma/PNET 
Lymphoma 
Multiple Myeloma 
 
Giant Cell 
 
Giant Cell Tumor   
Table 1.1: Classifications of bone tumors[1] 
Bone tumor generally refers to any abnormal growth from bone or in the bone. It can be a primary 
malignant tumor like an osteosarcoma, Ewing's sarcoma or chondrosarcoma. It can also be a 
metastatic carcinoma such as a breast cancer, lung cancer, prostate cancer, kidney cancer and 
thyroid cancer. It is important to differentiate between the various types of cancers that affect the 
bone because each has its own type of treatment and care. [1] 
Sarcomas and carcinomas are two different types of malignant tumors that can affect bones. They 
are derived from different cells. Sarcomas are derived from mesodermal (mesenchymal cells) and 
carcinomas are derived from epithelial types of cells. Sarcomas and carcinomas grow and spread 
differently.[2] 
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1.1.1. Sarcoma 
Sarcomas grow like "ball-like" masses and tend to push adjacent structures like arteries, nerves, 
veins away. They compress adjacent muscles into a pseudocapsule that contains microscopic 
projections of the tumor referred to as satellite nodules. The local growth of sarcomas like a ball 
enables resection in most instances. Sarcomas tend to arise primarily (directly) from bone.  
Sarcomas rarely spread to lymph nodes. It is derived from a particular type of cell referred to as a 
pluripotential mesenchymal cell. Under normal situations, mesenchymal cells in the body form 
bones, muscles, cartilage, connective tissue, blood vessels, blood cells, and nerves. Pluripotential 
means that cell has the ability to differentiate or grow along different pathways and form these 
various types of tissues. Under cancerous conditions, the mesenchymal cells that form a sarcoma 
can grow along a specific pathway and form tissue that looks like bone, cartilage, muscle, 
connective tissue, blood vessels as presented in table 1.1. Thus, it can have a bone sarcoma 
(malignant tumor of bone made up of mesenchymal cells) that is actually producing bone. The 
name given to this type of tumor is osteosarcoma (osteo means bone; thus osteosarcoma is a 
bone forming sarcoma). A patient can have a malignant bone tumor that produces cartilage. This 
is called a chondrosarcoma (chondro means cartilage). Malignant tumors that arise directly from 
bone are called sarcomas. Sarcoma is greek for "fleshy". The name was given to these types of 
tumors because of their appearance. They have a fleshy appearance when cut open and 
examined. Sarcomas are rare cancers and constitute about 1% of all cancers. [1] 
1.1.2. Carcinoma 
Carcinomas grow in an infiltrative manner and grow through infiltration or invasion of adjacent 
structures. They more easily invade adjacent nerves, blood vessels and muscles. They do not form 
a pseudocapsular layer and therefore it is difficult to determine its exact anatomic extent during 
surgery. This makes it more difficult to remove entirely with surgery. Carcinomas spread to lymph 
nodes, lungs, bones and many other organs depending on the type of carcinoma. Carcinomas 
involve bone secondarily, that is by spreading from another site such as the breast to the bone. A 
patient can have the primary site removed and treated (ie. the breast cancer removed) and years 
later develop a bone tumor/metastasis from the old breast cancer. 
Carcinomas are distinctly different from sarcomas. They are derived from cells that look like 
epithelial cells or glandular cells. These cells do not form bone, muscle, nerve, etc. They do not 
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have this ability. If a carcinoma is growing from a bone, it has usually come from a primary cancer 
in another part of the body. It is always considered cancerous and malignant because it has spread 
from another body part or another cancer. Breast cancer, lung cancer, kidney cancer, prostate 
cancer, thyroid cancer and gastrointestinal cancer are the most common carcinomas that travel or 
metastasize to bone. They can result in extensive destruction of the bone and can cause the bone 
to break/fracture. In some areas such as the pelvis and scapula, they can form large tumors that 
can involve the major nerves and blood vessels to the extremities. This is a serious situation. It can 
lead to uncontrollable pain and loss of the arm or extremity. The tumor in the bone is the same 
type of tumor as the primary carcinoma. For instance, if breast cancer has spread to the bone, the 
tumor in the bone is exactly the same as the breast cancer under the microscope. This is 
considered metastatic breast cancer to the bone. Carcinomas are much common and make up the 
majority of the cancers that occur yearly.[1] 
These large two family of cancer are characterized by similar symptoms:  
 1. Manifestation of pain without any traumatological event that does not decrease with the 
 assumption of an anti-inflammatory drug. Pain in the early stages can be contained but it 
 will gradually increase with time 
 2. Swelling that increases over time and in size  
 3. Presence of pathologic fracture occurred without trauma of the affected bone 
 segment[2]. 
1.2. Primary malignant bone tumors 
Primary malignant bone tumors include: 
• Osteosarcoma 
• Ewing’s sarcoma 
• Chondrosarcoma 
The three main forms of primary bone sarcoma are osteosarcoma and Ewing’s sarcoma, both of 
which primarily affect children and adolescents, and chondrosarcoma  tend to affect middle-aged 
and elderly patients.[2] 
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1.2.1.  Osteosarcoma 
 Conventional osteosarcoma usually arises in the medulla of long bones within the metaphysis, 
and over half are in the distal femur and proximal tibia, at the sites of greatest skeletal growth. 
Proximal humerus and femur and distal radius are also often involved, and no bone is exempt. 
Osteosarcoma spreads between the medullary trabeculae (figure 1.1), and penetrates and 
partially destroys the cortex to extend beneath and elevate the periosteum.  
 
Figure1.1 :Surgical specimen of distal femur containing an osteosarcoma which involve the medullary canal of the 
methaphisis [2] 
Effects of preoperative chemotherapy may modify both the progression and microscopic 
appearances by inducing necrosis and hemorrhage. This is important in assessing the response to 
therapy and informs the choice of postoperative regimen. 
Modern therapy combines preoperative and postoperative chemotherapy with surgery, often 
resection and endoprosthetic replacement or other reconstructions, rather than amputation.[2] 
1.2.2. Edwing’s sarcoma 
In contrast to osteosarcomas, which affect the metaphyseal long bones, Ewing’s sarcomas tend to 
arise in the diaphysis or metaphyseal– diaphyseal portion of long bones, pelvis, ribs and, rarely, in 
the skull, vertebrae, scapula, and short tubular bones of the hands and feet. Ewing’s sarcoma can 
also occur in the soft tissues without bone involvement.[3] 
The presenting features are of pain and swelling. Fever may suggest osteomyelitis, and tissue 
should be sent both for microbiology and pathology in these circumstances. The tumor arises 
within the medulla, both diaphysis and metaphysis, then rapidly penetrates the cortex and 
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periosteum to form a large soft tissue mass. Radiographs show large area of bone destruction and 
there is often a distinctive multilayered ‘onion-skin’ periosteal reaction. On microscopy, Ewing’s 
sarcoma is the prototypic malignant round cell tumor of childhood, consisting of sheets of small 
round cells with uniform nuclei. [2] 
The natural history of Ewing’s sarcoma is of early metastases both to lung and bone and bone 
marrow, with a particularly outcome for patients with large tumors notably in the pelvis 
and with systemic symptoms. Ewing’s sarcoma is best treated by a combination of intensive 
chemotherapy followed by local treatment, often with surgery and radiotherapy. 
1.2.3. Chondrosarcoma 
Unlike osteosarcoma and Ewing’s sarcoma, chondrosarcoma normally affects the middle aged and 
elderly. It usually arises as a primary tumor, but about 10% of cases arise in relation to a pre-
existing benign cartilage tumor. Chondrosarcoma may arise within the medulla as you can see in 
figure 1.2 or from the bone surface (peripheral). Tumor is  seen both in long bones, notably the 
femur and humerus, and in the axial skeleton, commonly the pelvis, shoulder girdle and ribs; 
rarely, chondrosarcoma occurs in the distal skeleton, for example in the tubular bones of the 
hands and feet. Most patients present swelling or pain, the latter is a sinister symptom when 
associated with a cartilage tumor in an adult. 
The typical central chondrosarcoma consists of sheets of cartilage, which often permeate between 
the cancellous trabeculae and tend to erode the bone cortex. A more aggressive tumor may 
penetrate the cortex to form a mass in soft tissue. Peripheral chondrosarcomas have a 
cartilaginous cap, with nodules of proliferating cartilage on the surface thicker than the cap of 1–2 
cm seen in a benign exostosis. In both forms, radiographs often show dystrophic calcification with 
peripheral rings, giving a popcorn pattern. Around 15% of chondrosarcomas metastasize, usually 
to the lungs. Although most chondrosarcomas grow slowly they tend to recur locally unless 
excised widely; this is a particular problem with central tumors, for example those of the spine and 
base of skull, which may cause death in the absence of metastases. As chondrosarcoma responds 
poorly to chemotherapy or radiotherapy, adequate wide surgical excision at the first operation is 
the key to cure. 
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Figure 1.2: Surgical specimen of a chondrosarcoma that has arisen in the medullary cavity and is confined by the 
cortex.[2] 
1.3. Treatment of bone tumor 
The most common techniques for the treatment of primary and metastatic bone tumors are: 
 Chemoterapy 
 Radioterapy 
 Surgical approach  
The use of chemotherapy in a patient with metastatic disease can help to control the disease, and 
the obtained results show a partial regression and temporary symptomatic relief. 
In most cases treated, tumor site and volume, age of patient are fundamental parameter for the 
develop of chemio-radio-surgical planification.   
In the Edwing’s sarcoma the introduction of systemic chemotherapy led to significant 
improvements in the prognosis in comparison with the prior extremely poor outcome with local 
therapy only [3]. In early studies, combinations of vincristine, cyclophosphamide, dactinomycin 
and doxorubicin resulted in survival rates of about 50% [4]. High-dose chemotherapy with 
busulfan/melphalan may yield benefits for patients suffering from metastasised Ewing’s sarcoma 
compared with conventional chemotherapy. 
Radiotherapy is advised only for inoperable lesions. Inoperability is defined by tumors that cannot 
be resected completely and in tumors of critical sites where complete surgery would result in 
unacceptable mutilation or is associated with a high risk of serious complications. A dose of 55 Gy 
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(with a shrinking-field technique after 45 Gy) is described to be a sufficient radiation dose in 
definitive radiotherapy.[4] However, large tumors may require higher radiation doses. 
Surgery is favored if a wide or at least marginal resection is feasible. Intralesional resections should 
be avoided as they are associated with a higher risk of peripheral and distant relapse.  
Surgery, if feasible, is generally preferred because it has resulted in better local control rates than 
definitive radiotherapy in many trials.[4] 
The main objectives of surgical intervention are prevention of fracture, maintenance of limb 
function, and palliative of pain. 
 The most common surgical approach was the using of a fixation device in combination with 
polymethyl methacrylate bone cement. Lesions larger than 3 cm with loss of cortical bone should 
be considered for supplemental fixation with bone cement. This may be accomplished while 
inserting an intramedullary device or cementing around a previously placed device. With plates, it 
is often best to treat the lesion, fill the defect with cement, and place a neutralization plate and 
screws. Screws placed into a bone-and-cement composite are exceptionally stable. Antibiotic-
impregnated cement has not been shown to provide additional benefit compared with regular 
cement. Cement impregnated with chemotherapeutic agents has been investigated, but thus far it 
has shown limited efficacy in terms of limiting local disease progression.[5] 
The medical needs that has been satisfied concern: 
 the inhibition of tumor growth,  
   strengthening of bone structure,  
 control and delate pain form the patient. 
1.4. Bone infection  
One possible complication connected to the bone tumor is infection, which can appear after 
tumor resection. Osteomyelitis  indicates an inflammation  of bone and marrow canal due to the 
infectious microorganism[6]. Staphylococcus aureus is among  the common bacteria  that causes 
this pathology[7].  
In figure 1.3 a osteomyelitis in a young girl, as a consequence of osteosarcoma, is reported. In  
panel B the radiographs show a bone resorption and loosening of the prosthesisthat created 
conditions for the proliferation of bacteria and, consequently, the failure of the implant. The 
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surgeron had to remove the implant and inject antibiotic in the tibia. Due to the fact that the 
patient didn’t response to the therapy, she underwent amputation on the upper knee. 
 
Figure 1.3: Osteomyelitis in a 19-year-old female of the right femur and prosthetic placement. Anteroposterior (A) 
and lateral (B) radiographs show bone resorption and loosening of the megaprosthesis. Biopsy was positive for 
osteomyelitis. Because of persistent infection, the megaprosthesis was removed, antibiotic pearls were inserted in 
the tibia (C). The patient was nonresponsive to antibiotics and subsequently had to undergo an above-the-knee 
amputation (D).[8] 
A problem concerning the use of antibiotics in the treatment of bone infections is the difficulty  of 
obtaining bactericidal levels of antibiotics in the infected tissues without reaching toxic systemic 
levels. The infected zone is filled by blood and serum which promotes bacteria growth and may 
lead to implant failure . Antibiotic should have an effect on bacteria without creating any collateral 
effects to other cells. Moreover, osteomyelitis are a nonspecific diagnosis, so they can present 
different approaches for the care managing. [8] 
                        
Figure 1.4: Complications of megaprostheses: in an 18-year-old female who received a megaprosthesis after 
resection of an osteosarcoma of the right femur. One year after resection, anterolateral (B) radiographs of tibia 
show extensive bone resorption consistent with aseptic loosening.[8] 
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Figure 1.4 reports another case study where the septic loosening caused the failure of the implant 
as a main consequence of bone resorption. [8] 
1.5. Hyperthermia 
The use of Hyperthermia as an adjunct to conventional oncology treatments has increased over 
the past two decades. It’s a non-invasive methods for increase tumor temperature stimulating 
blood flow, restarting the immune system, increasing oxygenation of the tissues. It’s well-
tolerated by practically all patients and it’s a nontoxic treatment. It works in synergy with 
radiotherapy increasing tumor control while minimizing damage to healthy tissue and permit the 
increment of radiation dose and with chemotherapy (cisplatin and related compounds, melphalan, 
cyclophosphamide, nitrogen mustards, anthracyclines, nitrosoureas, bleomycin, mitomycin C, and 
hypoxic cell sensitizers) increasing cellular uptake of drug and DNA damage and inhibition of  
cancer cells repair.[6] 
Hyperthermia provides an increasing temperature between 40-43 °C in the tissues in order to kill  
malignant cells and not health one. Moreover it also sensitize cancer cells to the previous mention 
treatments  (radiotherapy, chemotherapy, gene therapy and immunotherapy).[7] 
The duration of heating and high temperature levels achieved during treatment sessions influence 
a lot the number of death cells. Higher the temperature and longer time that heat is delivered to 
the tumor site, stronger the lethal effect and less the tumoral cells will be able to develop thermo 
tolerance phenomena[8]. Moreover not only these parameter are useful for the control of the 
phenomena but even environmental and vascular conditions are very important. Damage to 
cancerous cells is promoted by lack of oxygen, decreased pH, absence of nutrients and poor 
cooling, which are caused by pathological microvasculature within the tumor.[8] In general, the 
mentioned conditions are not seen in normal tissues which are not seriously affected by thermal 
treatment. As reported in figure 1.5 the biological hyperthermia principle is based by a 
vasodilatation of normal blood vessel that are able to increase the blood flow in order to dissipate 
the overheating. While tumoral cells that composed a solid tumor are unsupplied by this 
mechanism due to the pathological blood vessel structure which caused the final effect of necrotic 
or apoptotic death.  The vasculature disorder of tumoral cells and reduced blood flow favor 
hypoxia and acidosis. In this scenario hyperthermia will play in two different way: if the 
temperature applied is < 42°C the blood flow in the tumor increase in order to favors the action of 
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the chemotherapy while if the temperature is > 43°C the reduction of blood flow and the increase 
of hypoxia and acidosis lead the cancer cells in apoptosis.[7] 
 
Figure 1.5: Mechanism of tumor overheating with hyperthermia technique. In normal tissue the blood vessels 
increase our section when physiologically or artificially heated, consequently there is an increase of blood flow 
through the applied region and a decrease in its temperature. In the tumor site , pathological vessel are not able to 
dilate in fact most of these collapse because the heat is not dissipate by the tumor vessel. [4] 
1.5.1. Hyperthermia methods 
Depending on the location, depth and staging of tumor, there are three main clinical methods to 
generate an increasing temperature in the body: local, regional or whole body hyperthermia, 
which deliver heat to localized, advanced or deep seated and disseminated malignancy. [5] 
Local hyperthermia is applied for superficial tumors and can be achieved by external application 
of microwaves or radio-waves. Interstitial hyperthermia can be applied by inserting an applicator 
into the target volume and generating localized microwaves, radio waves, or ultrasonic waves.  
Endo-cavity hyperthermia is done by inserting an energy-inducing applicator in a natural opening 
of a hollow organ. These two techniques are a subtype of local hyperthermia.[5] 
Regional hyperthermia can be achieved with external heading radiofrequency, isolated limb 
hyperthermia, or cavity based hyperthermia. Several techniques have been used to raise 
temperatures in whole body hyperthermia with the aim of increasing tumor response to 
conventional chemotherapy (mainly in patients with metastatic disease). Temperatures of up to 
42°C, maintained for 60–90 min, can be achieved using radiant heaters with long infrared rays. 
Energies used to apply heat include microwaves (in the range of wavelengths from 433 MHz to 
2,45 GHz), radiofrequency (ranging from 100 KHz to 150 MHz), ultrasound, hot water perfusion 
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(tubes, blankets), resistive wire implants. Another way to deliver heat in the tumor site concerns 
the use of magnetic material like ferromagnetic  or  magnetic nanoparticles. After the  in vivo 
implant they can generate heat due to the stimulation with an alternate magnetic field.  
1.5.2. Hyperthermia in bone tumor treatment 
Taking into account the common aim of hyperthermia for the treatment of the tumors, it is 
important to point out that in order to apply the aforementioned techniques two methods are 
possible: the application of external energy using radiofrequency, microwave or ultrasounds with 
designed external devices or the application of an implanted magnetic materials that can provide 
an internal source of treatment. This type of hyper-thermic cancer therapy used magnetic material 
stimulated with the application of an alternate magnetic field. 
Some authors proposed the use of hyperthermia for the treatment of bone tumor with an external 
application of ultrasounds that has the aim to deliver the optimum energy to destroy the tumor 
mass. The system uses a spherically arranged applicators, the specific absorption rate ratio has 
been used to determine the proper heating domain of ultrasound driving frequency and 
therapeutic tumor diameter. The model has to be tailored respect to tumor size, tumor depth, 
ultrasound attenuation in the bone tumor tissue, the absorption energy from the bone and the 
frequency of the transducer. The application of ultrasound energy for hyperthermia is excessively 
reflected and absorbed by bone, this modality permits for the controlled heating of superficial and 
deep lesions. 
To deliver the ultrasound energy into the tumor site and to avoid the potential damage to the 
normal tissue, the specific absorption rate (SAR) in the bone tumor site has to be three times 
higher than that in the surface skin, tumor/marrow, and marrow/bone interfaces. The results will 
be very useful for the developing of a treatment planning for bone tumor with a design of 
ultrasound hyper-thermic applicator [8] .  
Fan et al. reported treatments of bone tumor with microwave induced hyperthermia on humans 
instead of a common surgery that create problem of infection, necrosis and local recurrence. The 
surgical procedure consisted of separating the tumorous segment from surrounding normal 
tissues with a safe margin, cooling the normal tissues (including the vital neurovascular bundle and 
the intra-joint structures) with a water circulation system while heating the tumor simultaneously 
with the microwave antenna array. The device was composed by a microwave generator at 2,4 
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GHz with a power range 0 – 200 W. Thermocouples were inserted in the tumor site and in the 
normal tissue for the monitoring of the temperature in real time. The results confirmed the 
decrease probability of oncological and operative complication and functional saving of limb.[9] 
Also microwave induced hyperthermia [8], laser-induced thermotherapy [10-12], and 
radiofrequency ablation [13] have been recently used especially for spinal and pelvic metastasis, 
but these therapeutic modalities are unsatisfactory for the lesions located in the long tubular bone 
of the limb, because pathological fractures cannot be treated without a surgical reinforcement of 
the bone lesion. 
One more effective technique for the care of bone tumors is magnetic hyperthermia. This method 
uses an external magnetic field that stimulates a per-implanted magnetic material in the 
generation of controlled heat, normally between 41°C and 43°C, into the body’s tissue destroying 
cancer cells [14-15]. The implanted material is able to magnetizing and produces hysteresis loss 
that are transformed into a controlled heat. The heating temperature depends on several factors, 
including materials properties, the magnetic field parameters (intensity, frequency) and bone 
tissue properties. [16]  This technology will be the object of a following chapter.  
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2.1. Poly methyl methacrylate 
Therapy for vertebral fracture, cemented hip prosthesis and other bone-related disorders, like 
bone tumor, have made acrylic bone cement based on poly methyl methacrylate (PMMA) integral 
part of the orthopaedic surgery. The material is named “bone cement” and it is a two component 
system composed by a powder and a liquid mixed together.   
There are two main type of bone cements: polymer-based and calcium phosphate-based. The 
focus will be on the first category of bone cements, in fact they are most common used in clinical 
orthopaedic surgery due to higher mechanical properties than the calcium phosphate bone 
cement in load-bearing application.  
The synthesis of bone cements is based on the polymerization of methyl methacrylate (MMA) 
monomers to poly-methyl methacrylate (PMMA).[1]  
2.1.1. Polymer chemistry 
Polymers are large molecules composed of individual repeating unit (monomer). Polymerization 
can occur by two different mechanisms: 
 With condensation reactions in which a functional group of a monomer reacts with a 
functional group on the growing chain of the polymer and the chain lengthening occurs 
with  a low molecular weight molecule (es. water) release. 
 With addition reactions in which the polymer chain grows by reacting directly with the 
double bond of a monomer and no molecules are released. The chemical mechanism for 
the polymerization of PMMA is shown in figure 2.1. 
 
Figure 2.1: Polymerization of PMMA by an addition reaction. MMA monomer reacts with a radical to generate e second radical 
that can attack the double bond of another MMA monomer. [2] 
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Polymerization begins by the addition mechanism in which a monomer becomes unstable by 
reacting with an initiator, a volatile molecule that is mostly commonly a radical (molecules that 
contain a single unpaired electron). Radical bond with monomers, forming monomer radicals that 
can attack the double bond of the next monomer by the mechanism shown in figure 2.1 
propagating the polymer chain. Since the radicals are unstable, the initiator are often added by as 
an unreactive peroxide in a much stable chemical form. Radical is formed when heat or light excite 
the peroxides molecule. For the application in which high temperature are not well tolerable, like 
bone cement, peroxide is cleaved by adding a chemical activator such as N,N-di-methyl-p-toluidine 
(DMPT) forming a phenyl radical that attacks the double bond of the MMA monomer. [1] 
2.2. Properties of PMMA 
PMMA has a linear chain and is a thermoplastic polymer with an un-crystallized structure whose 
vitreous transition temperature ranges from 110 up to 135°C. At room temperature it is hard, 
rigid, and brittle with little elongation. It is hygroscopic and, under extreme conditions, the water 
absorbed will act as a plasticizer and will modify the properties of the material. 
It has high mechanical strength, high Youngʹs modulus and low elongation at break. It is one of the 
hardest thermoplastics and is also highly scratch resistant. It exhibits good dimensional stability.[2] 
  
Physical properties Value 
Density 1,15-1,19 g/cm3 
Water absorption 0,3-2 % 
Moisture Absorption at Equilibrium 0,3-0,33 % 
Table 2.2: Physical properties of PMMA [2] 
2.3. PMMA bone cements 
As explained before, bone cements polymerize by radical-initiated addition reactions. The 
commercially available bone cements have two separate components: a powder containing pre-
polymerized beads of PMMA and a liquid containing MMA monomer. The benzoyl peroxide (BPO) 
initiator is incorporated into the powder and the chemical activator, DMPT, is incorporated into 
the liquid, so peroxide starts the polymerization mechanism only when the two phases are mixed. 
To prevent spontaneous polymerization during the storage, the easily oxidized molecule 
hydroquinone is also added to the liquid. DMPT splits BPO initiator at room temperature. The 
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growing polymer chains encapsulate the PMMA beads within a solid matrix. Another important 
component that characterized these material is the radiopaque inorganic phase. The most 
common are barium sulphate (BaSO4) or zirconium dioxide (ZrO2). The main reason of their 
addiction is the easier identification of the material status both during the surgical operation and 
in follow-up treatment after the implantation. In figure 2.2 a typical composition of a PMMA bone 
cement is shown. (1) 
 
Figure 2.2: Components of Commercially cements mixture[1] 
2.4. Cement properties 
2.4.1. Chemical properties 
Cement properties depend very much from the properties of the powder and the liquid 
component that react together. The effect of each component influences handling and setting 
time properties, polymerization temperature and mechanical properties.  
2.4.2. Liquid-to-Powder Ratio  
Liquid/powder ratio (LPR) of a bone cement has an important role in the aforementioned 
properties. LPR has to be chosen to keep a good trade off among all of them. 
Some scientific works show that greater LPR produce higher peak temperatures with an increasing 
of setting time. One possible explanation is that, at high LPR, an abundance of monomers react 
exothermically, increasing the peak polymerization temperature. However, the high LPR also 
decreases the relative concentration of initiator which is included in powder mix, so the 
monomers are activated slowly, increasing setting time [1].  
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Pascual et al. report a study on a modified PMMA bone cement with hydroxpropyl methacrylate 
(HPMA) in which a low LPR is used. The ratio causes a higher temperature peak and a shorter 
setting time is obtained while residual monomer content increases slightly.[5] 
2.4.3.  Mixing Methods  
One of the most important issue of PMMA bone cements is the presence of different mixing and 
handling techniques of the components. A first common technique is the manual mixing with 
spatula and bowl. It is a quite common surgery procedure when a patient undergoes to a 
cemented hip prosthesis operation. The surgeon, after the generation of a dough, introduces the 
paste into the hole between implant and bone. After that, in situ hardening appears. Air may 
become traps in the cement mixture, increasing porosity. Air weakens the cement and provides an 
interface for the develop of fractures and cracks. 
For the decreasing of voids, another way for the preparation of bone cement is the mechanical 
mixing technique with “vacuum mixing“, where powder and monomer are placed together in a 
mixing tube and the air is removed under pressure. The tube can placed into an injection gun from 
which cement can be extruded into the bone cavity. Vacuum mixing devices have been shown to 
reduce porosity by more than 44% compared with mixing with a bowl and spatula[1]. Another 
mechanical technique is a centrifugation which is found to remove pores and increase the fracture 
strength.  
All citied techniques produce a mechanical interlock between the bone and the solidified cement 
that maintains the strength but does not promote any chemical bond between the implant and 
the bone.[6] 
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Figure 2.3:A comparison of fatigue strength of hand-mixed and vacuum-mixed bone cement.[6] 
As presented in figure 2.3, fatigue strength is evaluated as a function of mixing method. The trends 
of stresses values for cements produced by vacuum mixing are higher than those produced by 
hand-mixing.  
2.4.4. Handling and setting time properties 
During the synthesis of the material it is possible to distinguish three different times: 
 Dough time, which is the time between starting mixing powder and liquid and the moment 
when the cement is inserted in the bone cavity  
 Working time, which permits the workability of the cement in the bone cavity  
 Setting time, which is the time that elapses for the hardening of the cement. After that 
time any other modification in shape and quantity is possible. (figure 2.4) 
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Figure 2.4: Setting time test: evaluation of the hardening time 
In figure 2.4 a typical hardening curve of a PMMA bone cement is shown, with the identification of 
three different  times. As evidenced in the curve, the slope of the curve shows the setting time.  
The peak of the curve permits the evaluation of the maximum polymerization temperature which 
has to be the lowest as possible in order to minimise necrosis of surrounding bone .  
The workability properties of PMMA bone cements are evaluated with curing parameters and any 
further modification of the chemical composition of PMMA has to be evaluated as a function of 
these parameters.  
An ISO 5833-2008 has standardized the test in order to provide a methods for comparison 
different curing parameters of different cements.  
For each unit of cement, the setting time is measured from beginning of mixing until the 
temperature of the polymerizing mass reaches the setting temperature defined as: 
    
 
maxT = is the highest polymerization temperature measure 
Tamb= is the recorded room temperature 
The standard provides some restrictions that the bone cement has to respect before the in vivo 
application (table 2.2). 
 
 
 
 
(2.1.1)                             
2
max TambT
Tset


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Mixture 
Dough time Setting time Maximum temperature 
Average                   
 
min 
Maximum 
deviation  
from average 
 
min 
Average 
 
min 
Average 
 
°C 
Maximum 
deviation from 
average 
°C 
 
Dough state 
usage 
≤ 5 1,5 3 to 15 90 ± 5 
Table 2.2: Curing parameter requirements [3] 
Figure 2.4  evidences that the slope of the setting curve does not change at the beginning but at a 
certain point it suddenly increases. For this reason the setting time evaluation is crucial because it 
informs that in a few minutes the cement will be not workability nor injectable into the bone 
defect and the surgeon has to operate before this time limit. 
2.4.5. Radiopaque agents  
Radiopaque compounds interrupt the polymerizing matrix and produce discontinuities in the 
material that can act as fracture initiation sites, diminishing mechanical strength with a not clear 
effect on polymerization temperature and setting time [1]. To guarantee the structural integrity of 
radio-opacified cement, it has been noticed that zirconium is structurally superior to barium. 
Homogeneity of mixed cement is key factor and that a not homogeneous dispersion of barium 
particles leads to fractures formations. New cross-linking agents and preparation methods that 
enhance cement strength have been reported. The incorporation of these additives into the 
cement formulations will minimize any loss of strength or durability due to radio-opacifiers. 
Ginebra et al. reports that the radio-opaque agents, both inorganic and organic, have a significant 
effect on the mechanical properties of the acrylic bone cement. The effect of the inorganic fillers 
depends on their size and morphology. The addition of zirconium dioxide significantly improves 
the tensile strength, the fracture toughness and the fatigue crack propagation resistance. In 
contrast, the addition of barium sulphate produces a decrease of the tensile strength, but does 
not affect the fracture toughness and improves the crack propagation resistance.[7] 
2.4.6. PMMA beads size  
The average diameter and size distribution of PMMA beads play an important role in the cure 
properties of bone cement.  This component has a double function: a structural role as a 
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component of the cement matrix and as a heat sink–dissipating energy released by the exothermic 
polymerization of MMA monomers. Samples containing PMMA particles with larger mean 
diameters and widespread distributions of particle size have lower peak polymerization 
temperatures and longer setting times [1].  
Moreover the concentration of activator and the free radical initiator influence the peak 
temperature, the setting time and the mechanical properties of the cured cement.  
 
Figure 2.5: Relationship between average size of PMMA and the maximum temperature reached during the polymerization 
process of acrylic bone cement formulations[2] 
In figure 2.5 a linear correlation between the average particle size of PMMA and the maximum 
polymerization temperature is reported. Increasing the particle size, the maximum temperature 
statistically decrease . The fact could be explained in a much higher capacity of large beads (50-60 
μm) to dissipate the heat in an effective way respect to smaller particles with a size < 20 μm. 
If the polymerization temperature reaches or is near to the boiling point of MMA monomer, 
around 100°C at standard pressure, the vaporization of MMA molecules could give rise to the 
appearance of voids inside the cured system. This is another interesting reason to lower the 
polymerization temperature.[2] 
2.5. Mechanical properties 
In table 2.3 a comparison between the mechanical properties of the cement and the human bone 
is shown. The compression strength of the PMMA is quite comparable with the same value of the 
cortical femoral bone.[8] 
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Table 2.3: Comparison between the mechanical properties of human bone and the PMMA bone cement[8] 
Mechanical properties Value 
Hardness, Rockwell M 63-97 
Tensile Strength, Ultimate 47-79 MPa 
Elongation at Break 1-30% 
Tensile Modulus 2,2-3,8 GPa 
Flexural Modulus 3-3,5 GPa 
Table 2.4: Mechanical properties of PMMA [4] 
Compression tests are evaluated referring to ISO 5833 – 2003 specification: the ultimate 
compressive strength (table 2.4) and Young Modulus should be estimated from the stress strain 
curve using a 2% offset role and the slope of the initial straight section of the curve. The 
mechanical results,  are influence by two main factors:  
1. Chemical parameters: quantities of stabilizers, initiators and radiopaocifiers, presence or 
absence of a copolymer, the powder size and distribution and the rate of change of 
viscosity with time. 
2. The mixing methods: this is an important parameter for a given formulations. This factor 
influences the number and the size of micro- and macropores.[10] 
Even flexural and shear mechanical properties depends very much from cement formulation, 
mixing method, curing and aging conditions. 
The method used to mix the liquid monomer and the powder has a significant role in determining 
the final quality of bone cement. An inadequately mixed cement usually presents a high degree of 
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porosity . As a consequence, a lot of studies have been conducted on the parameters and variables 
that affect the quality of bone cement prepared by different mixing methods and devices. 
Two important factors have to be taken into account: the depth of penetration of the liquid 
monomer into the powder (l), process that is describable using the Washburn equation, and the 
associated Reynolds number, Re.[11] The study reports in [10] compares variability of the porosity 
of the cured cement and its bending modulus and bending strength when mixed with a new 
automated device, compared to the values obtained when the cement is mixed using a 
commercially-available vacuum cement mixer, that is in current clinical use. 
 
Figure 2.6: Mixing and temperature effect on the porosity of acrylic bone cement 
The porosities report in figure 2.6 indicate that there is a statistical difference between cement 
mixed at 4°C and at 25 °C. The cements cured at 4 °C show an almost 50% decrease in porosity 
compared to those cured at 25 °C. These reduced porosities depend on the decrease of air 
entrapped in the cement at the moment of mixing. The material stored at low temperature has a 
lower viscosity that could influence the decrease of cement porosity.  
The comparison of two cement mixing methods has shown a decreasing porosity of 20% using a 
standard mixer in comparison to an automated mixer. The same trend is observed comparing 
storing procedures at 4°C and 25°C respectively. Velocity and mixing motion of the cement within 
the automated mixer caused more air entrapment than conventional paddle stirring.  
The mechanical tests have shown a statistical difference between two storage temperatures. At 
4°C an increase of bending modulus and strength of 8% and 14% respectively can be observed in 
respect to higher temperatures. As mentioned before the decrease of air entrapment during the 
mixing phase and the lower initial storage temperature have improved the mechanical properties. 
[11] 
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2.6. Biological properties 
PMMA bone cement is classified as an inert material. It is noted that after a certain period from 
the implant of the cement, there is the formation of a fibrous membrane between the bone and 
the cement, with a thickness between 50 m and 3 mm, which allows micro motion occurrence, 
causing pain into the patient and the space for wear particles accumulation. A possible solution to 
overcome this problem at the interface is the use of a bioactive bone cement[19]. 
2.7. Problems 
For orthopedic applications, PMMA is used as a filler and it has to guarantee the transfer of the 
load from the metallic prosthesis to the human bone, avoiding or minimizing stress shielding 
phenomena. The human bone does not become osteoporotic or subjected to restorable events 
due to the implant of the material. The material should substitute or fill a bone without modifying 
its physiology and functionality.  
When a new material is implanted into the body an inflammatory response occurs, with the 
recruitment of macrophages and other repair cells.  The worst situation consists in the toxic 
behavior with the death of surrounding tissue. An inert response create a thin fibrous layer at the 
interface of 1-3 m and no bond between the tissues and the implant. On the contrary, bioactive 
materials are able to stimulate a chemical reaction with living tissues. Hydroxyapatite, bioactive 
glasses and glass-ceramics are typical examples. 
In the previous classification, PMMA bone cement is classified has an inert material. It is well 
known that when it is implanted in vivo the formation of fibrous collagen capsule occurs., This 
represents a human response without any osteointegration process. It has been evidenced that a 
stable bone-implant interface has to be achieved for a long duration of the implant.  
Thermal bone necrosis and weakling of the local blood flow are effects generated during in situ 
curing reactions. Moreover, a chemical necrosis appears with the release of the monomer in the 
human blood stream, even after several years from the implantation. But the main cause of failure 
for a PMMA implant is the septic loosening connected with a problem of infections evoked from 
the cement particles in contact with surroundings tissues.[8] 
Loosening is a multi-factorial process and that originates from several causes. Among them, the 
most important consists in the fatigue failure, that comes from: 
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 pores in the cement  
 stress concentrations at the implant/cement interface  
 debonding at the prosthesis/cement interface  
 bone resorption, causing stresses in the cement[8] 
Huiskes proposes some failure scenario of PMMA bone cement  used for fixation of hip prosthesis 
that can adapt very well to a common cause of failure of this material even when it is used for 
other applications[9] 
The failure scenario includes: 
1. Gradual cracking of bone cement starting from interface debonding, pores in the cement 
or increased stress due to peripheral bone losses. 
2. Generation of wear particles or debris, that develop bone damage with osteolysis at the 
interface. 
3. High micro motion of the implant respect to the bone, that can change the bone ingrowth 
mechanism and, consequently, the strength fixation, which in turn is not high enough to 
sustain weight-bearing load. 
4. Stress shielding, which can be another consequence of failure, due to the high stiffness of 
the implant respect to the bone, that can lead to a degeneration of the fixation. A 
concentration of the load occurs mainly on the PMMA bone cement if a poor 
osteointegration is present. The bone is not loaded due to very different Young modulus 
between bone and PMMA, Being the last higher that the first, and consequently bone 
resorption occurs.[9] 
5. The possible release of cement particles, that can directly interact with the surrounding 
tissues, evoking an inflammatory response and increasing bone destructions. [10] 
Looking for an innovative solution to the aforementioned drawbacks, some studies will be 
presented regarding the synthesis and the characterizations of composite bone cements with high 
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osteointegration properties. The goal is to design a material with a good compromise among 
handling properties, bioactivity and adequate mechanical characteristics. 
2.8. Bioactive PMMA bone cement 
In order to increase the adhesion capability at the interface cement- bone , many research groups 
have proposed a PMMA composite material where polymer is the matrix and a glass or glass 
ceramic particles are the disperse phase.[12 -23] 
W.F. Musa et al. develop a bioactive PMMA-based bone cements for prosthetic fixation with high 
bioactivity, high mechanical properties and good handling properties. Commercial PMMA powders 
different in molecular weights, particle size and shape have been used and loaded with different 
amount of Apatite/Wollastonite (A/W) bioactive glass-ceramic. The compositions of the 
investigated formulations are reported in Table 2.5.[20] The authors perform the evaluation of 
handling properties, mechanical tests and in vivo animal test to verify the bioactive performances 
of the materials.  
 
Table 2.4:Compositions of different PMMA-based bioactive cements [20] 
The loading of dry-silanized Apatite Wollastonite-Glass Ceramic filler to the PMMA cement in 70 
wt% ratio maintained both bending strength and fracture toughness similar to the control. and the 
osteoconductivity of the cement increased from 32.1 ±15.8 % to 55.5 ±10.8% for B-CMW1 
(commercial Simplex cement matrix). The interaction between the bone and the implant is 
positively affected, due to the bioactive glass ceramic dispersed into the PMMA matrix, as 
demonstrated by the in vivo test on six group of rats where the direct contact between the bone 
and the bioactive cement is evaluated . 
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Figure 2.7: SEM microphotographs showing axial sections of rat tibiae 8 weeks after the implantation.(a) bioactive bone cement 
and(b) control cement  with no bioactive phase; 
Figure 2.7 reports a SEM microphotograph showing a section of a rat tibiae with the injection of a 
bioactive bone cement (a) and with a control material (b) after 8 weeks from the implantation. A 
very high level of osteointegration is noticed in figure 2.7a respect to the poor property of the 
PMMA  
Another example of bioactive bone cement was present by Yamamuro et al. [21] where an apatite 
wollastonite glass ceramic was added to a cement based on the bisphenol-a-gycidic methacrylate 
(Bis-GMA) resin. The main advantage in using a different matrix was explained in a decreasing of 
the curing temperature in respect to PMMA.  
The glass ceramic with the composition CaO 44.7, SiO2 34.0, P2O5 16.2, MgO 4.6 and CaF2 0.5 
(weight ratio) was melted in a SiC furnace at 1500°C. The melt was quenched in water then 
pulverized with an alumina ball mill. The average diameter of the glass-ceramic powder particle 
was 5 m. The powder was added to the resin and maximum polymerization temperature and 
mechanical properties were evaluated together with animal experiments.[2121] 
Histological examinations reveal the formation of fibrous tissue between PMMA cement (used as a 
control) and the bone, while the bioactive cement bonds to bone at 3 and 6 months after surgery 
through a CaP-rich layer. This CaP-rich layer, about 30 m thick, is crystallographically confirmed 
to be an apatite layer.[21] 
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Figure2.8: HAp precipitation at the bone implant interface. The effect is due to the presence of a bioactive phase into the 
polymer. AC is a bioactive bone cement while B is a bone [21] 
After three months new regenerated bone is observed at the bioactive cement surface, and the 
bone between the cement and the femoral endosteum become dense. (figure 2.8) 
Hamizanh et al. [22] reports the realization of a PMMA bone cement modified with the addition of 
a bioactive glass-ceramic phase. The glass-ceramic has been produced by melting techniques and 
controlled crystallization. The synthesized glass-ceramic composition is 55 SiO2, 10 Na2O, and 35 
CaO (wt %) 3 wt % of P2O5 .[22] A comparison between bioactive PMMA bone cement and 
hydroxyapatite bone cement composites is performed.  
The sample with 16 wt % of filler loading broke at a higher strain compare with that at 4 wt %. 
 
 
Figure 2.9: XRD patterns of bioactive glass-ceramic before and after soaking in SBF for 7 days while, GCBC4 is a composite bone 
cement with 4% of glass ceramic, and GCBC8 is bone cement with 8% of glass ceramic after soaking in SBF for 7 days.[22] 
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Figure 2.9 evidences the X-Ray Diffraction pattern of the glass ceramic before and after  bioactivity 
process . A low peaks of apatite is noticed only on glass ceramic after soaking for 7 days in SBF. 
While on the composites GCBC4 and GCBC8 no apatite is detected , but only a wide halo at 2Θ= 
10°-23° which indicate the presence of an amorphous phase.  
The authors affirm that the glass ceramic phase disperse in the polymer is not sufficient to 
produce the precipitation of apatite on the surface of the composite.  
Shinzato et al. [23] propose a bioactive PMMA bone cement containing a glass of different 
particles size in order to study how they influences the mechanical properties and the 
osteoconductivity of the composite. Four different formulations of cement have been prepared, 
containing glass particles with a diameter of 4, 5, 9, 13 m respectively. The glass belongs to the 
system MgO-CaO-SiO2-P2O5-CaF2 and it is mixed in a proportion of 70% with the PMMA. The 
cement is inserted into the medullary canals of rat tibiae and the bone-cement interface is 
examined by scanning electron microscopy (SEM). Affinity index is used to measure the 
osteoconductivity of the material. The index is calculated as the length of bone in direct contact 
with the cement surface without any intervening soft tissue divided by the total length of the 
cement surface, and this value was multiplied by 100 [23]  
 
Table 2.6: Mechanical Properties of Composite bone cements after 1 day soaking in SBF at 37°C [10] 
The mechanical results shown in table 2.6 evidences a decreasing trend in bending strength with 
the increase of particle size, even if the values of four tested formulation remain significantly 
higher than that of the control (PMMA). The Young Modulus does not follow the same trend of 
the bending strength, in fact no variation has been evaluated with the increasing of particle size. 
SEM evaluation for all four types of cement shows a very good interaction with bone at 4 and 8 
weeks. The affinity index decrease at 4 and 8 weeks with the increase of the glass particles.  
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Figure 2.10: (a) bioactive cement with 4 m disperse glass particles and (b) bioactive cement with 13 m disperse glass particles 
in rat tibiae at 4 weeks after implantation. Direct bone formation was observed on two different bioactive glass cement 
formulations without intervening soft tissue layer. C, cement; B, bone. Original magnification at 400x.[23] 
In figure 2.10 a better result is presented, using a bioactive particle phase in the polymer matrix. C 
is the cement and B is the bone; the cement is very well osteointegrated with a continuity 
solution. A very good interconnectivity between the bone and the composite and direct bone 
formatioare evidenced.[23] 
 
Figure 2.11: Scanning electron micrograph of a post-mortem specimen. The image on the left  shows multiple cement fractures 
and adjacent fragmentation to the osteolysis area. P is a cement plug at the tip of the prosthesis; FV is  a fracture through voids 
in the cement; C is bone cement; b is bone; L is focal lysis in the cortical bone. On the right a detail where it is possible to 
distinguish the fracture of the PMMA cement and behind it the fracture and resorption of cortical bone.[24] 
In figure 2.11 a scanning electron micrograph of a post-mortem specimen of a failed cemented hip 
prosthesis is reported. Many fracture of the PMMA bone cement combined with a large zone of 
osteolysis and bone resorption are very clear. This is an example of non-bonding effect between 
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the implant and the tissue[24]. This local cement failure had generated particulate debris and 
endosteal bone lysis adjacent to the local cement fragmentation. 
In conclusion , the addition of a glass ceramic phase to a bone cement has to be take into account 
for improving the performance of the material in the interaction with bone.  
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3.1. Glasses  
A glass is an amorphous material obtained by a progressive stiffening of a liquid that does not 
crystallise during a fast cooling (figure 3.1).  
 
Figure 3.1: Cast of a glass into a mould[1] 
In a crystalline solid material a transition between a liquid to a solid state become in a 
discontinuity way at a precise temperature called solidification temperature.  
In an amorphous material the passage from a liquid to a solid becomes with a progressive and 
continuous increase in viscosity during cooling up to completely stiffness. 
 
Figure 3.2: Mechanism of glass formation Specific volume vs temperature diagram . [2] 
During the cooling of a liquid the elementary structures (atoms and molecules) are able to move 
and get close one to another. At a certain temperature value of the diagram evidenced in figure 
3.2 , named kinetic cross road, two scenarios are possible: an abrupt decreasing of specific volume 
at a constant temperature, T melting for a solid, where the unit structures join themselves in order 
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to form a crystalline solid. The process is completed only when the crystals  have reached a 
maximum possible order.(figure 3.2) 
The second solution regards the formation of a glass, in which there is a transition from an under 
cooled liquid where the atoms and molecules rearrange up to glass state. The movements are 
blocked and the structure of a liquid becomes fixed and is no longer temperature-dependent. The 
passage from a state to another occurred with a progressive increase of viscosity.  
The glass is characterized by a Transition Temperature (Tg) which is an useful indicator of the 
appropriate temperature at which the under-cooled liquid converts to a solid during cooling.  
On the contrary, Tg, indicates when the solid begins to behave as a viscoelastic material during 
heating. As we can see from the diagram in figure 3.2, the structure of a glass is more open than 
the structure of a crystalline solid. An amorphous material is characterized by a continuous 
reduction of volume, occurring during the temperature decrease, and by a change of curve slope 
at a glass transition temperature. 
During the cooling, the glass is characterized by a spatial organization with a short range order and 
an high degree of long range disorder, similar to the liquid from which it originated. 
 
Figure 3.3:Difference between crystalline and amorphous SiO2 [1]  
Figure 3.3 evidences the structure of the amorphous silica respect to the crystalline silica. In the 
first panel the silica tetrahedrons are disposed regularly in a three dimensional lattice network; 
this structure presents a long range order and periodic atomic arrangement, which is typical of a 
crystalline solids; while in the second panel the silica glass is characterized by a long range 
disorder. However a glass can be defined as a material with a short range order composed by silica 
tetrahedron . 
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Zachariasen proposed a glass formation theory according to silica crystals, which form glass 
instead of recrystallizing after melting and cooling, have a network and not a close-packed 
structures. This network is composed by tetrahedral which are connected at all four corners, 
Network is not periodic and symmetrical as in crystals. It extends without a preferential direction 
and in fact glass is considered an isotropic material. Its properties do not depend from a 
preferential direction  
The theory of Zachariasen proposes four rules for the formation of glass. These rules affirm: 
1. Each oxygen atoms is linked to no more than two cations  
2. The oxygen coordination number of the network cations is three or four 
3. Oxygen polyhedral shares only corners and not edge or face  
4. At least 3 corners of each oxygen polyhedron must be shared in order to form a 3-
dimensional network. 
Sufficient network cations must be present to allow a continue  open structure to form a glass.[3] 
Another theory was proposed by Stanworth, he classified the oxides that compose a glass into 
three groups: glass formers, intermediate and modifiers on the basis of the electro-negativity of 
the cations. The only anion is the oxygen and the theory approach is based on the evaluation of a 
cation-anion bond. Cation that form covalent bond with oxygen should act as former and 
produced good glasses. Cations with lower electronegativity form more ionic bonds with oxygen 
so they cannot form glasses by themselves, but they can partially replace cations from the 
previous group. Since the behavior of these ions is transitional between the cations that form a 
glass and other which never form glasses, they are defined as intermediate. Cations, which have 
very low electronegativity and therefore they form highly ionic bond with oxygen, never act as a 
network formers. Since these ions can only modify the network structure created by network 
forming oxides, they are termed modifiers. As it will discuss later, they are very important in the 
bioactive and antibacterial properties of the glass. In table 3.1 there are some example of 
inorganic oxide divided in these three categories.[3]  
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Table 3.1: Classification of inorganic oxides in the structure glass theory[5] 
Bond strength is another criterion for predicting the glass formation. Sun [3] states that strong 
bond prevents reorganization of the melt structure into the crystalline structure during cooling 
and thus promotes glass formation. The bond strength is defined as the energy required to 
dissociate an oxide into its atomic component. The best glass former are characterized by a high 
bond strength. Using this criterion the division into glass former, intermediate and modifiers is 
also applicable.  
  Figure 3.4:Glass structure: effect of alkali oxide[1,5] 
In figure 3.4 a typical structure of silica glass is shown, it can distinguish the silica tetrahedron with  
bridging oxygen (BO), which connect one tetrahedral to another and a non-bridging oxygen (NBO) 
which interrupts the silica network. The NBO usually are surrounded by some ions like Na+ or Ca++ 
which modified the network. Sodium and calcium ions do not form glass alone and cause a 
breakdown of the glass network, they can easily diffuse inside the material, their incorporation 
aims at reducing melting and working temperatures. In fact Na2O decrease the melting 
temperature of the glass and CaO increase the chemical durability. [3] 
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3.2. Glass ceramic materials 
When a liquid became solid by a vitrification process the cooling rate is higher than the 
crystallization rate.  
A de-vitrification process is expressed by nucleation and growth of  a crystalline species. It can 
happen if the glass remains for a long time at a certain temperature in which the speed of 
crystallization rate is high. 
The crystallization process requires the presence of a nucleus, on which the crystals will 
subsequently grow to a detectable size.  
The passage from the liquid state to a crystalline phase will not became instantaneously in all the 
mass because should be a cooperative movement of all atoms of the material but for progressive 
growth of nucleus composed by clusters of few hundreds of atoms.  
Both the nucleation crystal and growth processes are thermally activated, in fact they require the 
overcoming of energy barriers by thermal energy.  
A glass-ceramic can be obtained from a base glass by controlled crystallization (figure 3.5): the 
glass, after its synthesis, is subjected to a heat treatment at a temperature T1, at which it is 
maintained for a certain period of time in order to promote the formation of nuclei, which act as 
centres of crystallization. In a next step, these nuclei increase by a heat treatment at a 
temperature T2 (growth) greater than T1.  
 
Figure 3.5: Nucleation and crystallization thermal treatments[1] 
The new crystals produced in this way grow directly in the glass phase and at the same time slowly 
change the composition of the remaining glass.  
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3.3. Bioactive glasses 
Bioactive glasses are a particular category of glass characterized by: 
 A typical composition of SiO2, CaO, Na2O, P2O5 
 A SiO2 content inferior than 60% mol  
 High presence of Na2O and CaO 
 High ratio CaO/P2O5 
 The Na2O-CaO-SiO2 diagram in Figure 3.6 is used for the design of a bioactive glass . This ternary 
diagram is divided in different zones and each zone has different chemical characteristics. 
 
Figure 3.6: The graph shows compositional dependence (in weight percent, %wt) of the ternary compounds for the identification 
of the best bioglass formulation P2O5 is constant at 6 %wt.[4] 
The chemical glass compositions in the middle of the diagram, in region A, can create a chemical 
bond with bone. In fact region A defines the bioactive bone-bonding boundary. Silicate glasses 
inside region B, such as glasses used for window or bottle behave as inert materials and highlight 
formation of a fibrous capsule at the implant–tissue interface, in fact the reactivity of these 
materials is very low due to the presence of a high SiO2 content. Glasses within region C are 
resorbable and disappear within 10–30 days of implantation, because the presence of calcium 
oxide is too low and the durability of the glass is not guarantee. Glasses within region D are not 
technically practical and, therefore, they have not been tested as implants due to the lack of 
network former compound. In the middle of the diagram in zone E there is the composition of 
Bioglass® that Hench discovers in 1970. The composition of Bioglass® is 45% SiO2, 24.5 % CaO, 24.5 
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Na2O, 6% P2O5 (% in wt). The discovery of this material permitted the explanation of the bioactivity 
process that takes place when the glass is put in contact with biological fluids.[4]  
The most important application of these materials is the orthopaedic surgery where there is an 
elevated request of material which can induce a fast osteointegration between the bone and the 
implant.  
3.3.1.  The bioactivity process 
As mentioned before, glasses for biomedical use can be classified into three categories: 
resorbable, bioactive and inert materials. A bioactive material is defined as a material that present 
a specific biological response at the interface with tissue. 
A bioactive glass undergoes to a surface dissolution in a physiological environment, which cause 
the formation of a hydroxycarbonate apatite (HCA) layer on its surface. An elevated solubility of a 
bioactive glass causes an increase of bone tissue growth.[4] 
The bioactivity process is a time dependent surface modification. This can happen in vitro in 
presence of a simulated body fluid (SBF) or in vivo with biological fluids contact. 
The expected result is the completely osteointegration of the material with soft or hard tissues.[6] 
For the glass-ceramics, generally, the process of bioactivity depends only on the amorphous 
phase.  
The glass dissolution causes both the chemical composition and pH solution variations. The 
formation of HCA on bioactive glasses and the release of soluble silica and calcium ions to the 
surrounding tissue are key factors in the rapid bonding of these glasses to tissue. 
The bioactive process can be divided into 11 stages: stages 1–5 are chemical and can occur in vitro, 
stages 6–11 are biological and occur only in vivo: 
1. The modifiers ions, Na+ and Ca++, produced an ion exchange between them and the 
hydrogen ions present in the solution. 
Si-O-Na

H

OH

Si-OH

Na

(aq) OH


 In this step the pH of the solution increases (> 7,4) as a result of the decreasing of H

ions 
in the  solution, since they are substituted by cations. Figure 3.7a 
2.  Due to the ion exchange of the previous step there is the formation of the silanols at the 
material surface. The hydrogen ions combine with the non bridging oxygen due to rupture 
of Si-O bond.  
Bioactive ferrimagnetic and antibacterial glass ceramic 
 
48 
Matteo Bruno 
   Si-O-Si H2O Si-OH OH-Si 
 For the same reason the release of soluble silica in a Si(OH)4 form happen. 
3. The silanols polycondesate of and create a silica gel: the re-polymerized silanols provide Si-
O-Si with high water content. Figure 3.7c 
SiOH + SiOH  Si-O-Si + H2O  
 This silica layer acts as a preferential nucleation site for the CaP layer [11] 
4. Precipitation of an amorphous phase enriches of Ca++, PO4
3-, CO3
2- on the SiO2-rich 
layer.Figure 3.7d 
5. Crystallisation of the amorphous CaO-P2O5 film by incorporation of OH- and CO3
2- anions 
from solution to form a mixed hydroxyl carbonate apatite (HCA) layer. Figure 3.7e 
 
 
 
Figure 3.7: Chemical bioactivity steps[1] 
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6. Adsorption and desorption of biological growth factors, in the HCA layer (continues 
throughout the process), to activate differentiation of stem cells. 
7. Action of macrophages: they intervene always when a foreign body invades the body. 
8. Attachment of stem cells on the bioactive surface.  
9. Differentiation of stem cells to form bone growing cells, osteoblasts. 
10. Generation of extracellular matrix by the osteoblasts to form bone. 
11. Crystallisation of inorganic calcium phosphate matrix to enclose bone cells in a living 
composite structure.[1-4]  
 
Figure 3.8: Scanning electron microscopy of different step of bioactivity process[1] 
Figure 3.8 shows three steps (a, b and c) and one magnification (d) of the bioactivity process: in 
figure 3.8a the formation of a silica gel on the surface of a glass, with some isolated precipitates, is 
represented. Here an early stage of bioactivity is reported. In figure 3.8b and 8c the amount of 
precipitations increases and covers the whole surface of the glass. A calcium phosphate laver is 
forming. Figure 3.8d shows a magnification, in which it is possible to see the typical morphology of 
hydroxyapatite formed at the end of 5 steps of bioactivity. This behaviour provides an useful proof 
of material osteointegration capacity . 
The bioactivity depends a lot from the chemical composition of the glass and from the kinetics of 
exchange with surround fluids.  
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Figure 3.9: Bioactivity profile from bulk bio glass to bone[1] 
Figure 3.9 shows a theoretical reaction layer between an implant and the bone. The bulk glass 
contains silica, calcium and phosphorus, when the glass is put in contact with biological fluids 
there is the formation of silicon rich layer, which acts as substrate for the precipitation of Ca-P rich 
layer. This last layer, very similar in morphology and composition to the natural HAp, integrates 
itself with bone. With the increasing of the distance from the bioactive substrate the silicon rich 
layer decrease respect to an increase of calcium and phosphorus intensity . 
 
Figure 3.10: shows the SEM images of a cross-section of glass, soaked in simulated body fluid for: (a) 2, (b) 3, (c) 4, and (d) 5 
weeks with its line scan profiles, the reaction layer is characterized by the different gray tones: G-glass, Si-Silicon-rich layer, CaP-
calcium and phosphorous-rich layer. (e) Shows the reaction layer Si and CaP development with time in this type of glass.[11] 
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De Arenas et al. showed a cross section of a bioactive glass at different times where it possible to 
distinguish the bioactivity steps and the trend of the ions, the silica gel and the HAp formation. 
Reaction layers of silica and CaP depend on time soaking of the glass; in fact the trend of the 
calcium and phosphorus increase with increasing of soaking time in SBF(figure 3.10). [11] 
3.3.2. Osteoinductive behaviour of bioactive glasses 
Another important property of bioactive glasses regards their capability to slowly degrade and 
dissolve when they are implanted. Release products stimulate progenitor cells to differentiate into 
a bone cell (osteoblast). The pathway of stimulating genes is associated with osteoblast 
differentiation. This phenomenon is called osteoinduction. The use of bioactive glasses encourages 
the formation of new bone in two different way by osteoconduction, and by osteoinduction. In the 
first the glass establish a chemical bond with the existing bone. The stimulation of new bone on 
and along its surface is confirmed by the bioactivity process . In the second the material is able to 
activate genetic pathways for the production of new bone cells.[7] 
In a research work[8] Hench clarified the genetic activation mechanism in the differentiation of 
bone cells induced by Bioglass®specific ion release .  
In the developing of genetic theory of bone regeneration, he stated that not only the glass but also 
the ionic dissolution products released from 45S5 influence and control the cell cycle of osteogenic 
precursor cells. Cells that were not be able to achieving a fully differentiated phenotype 
characteristic of mature osteocytes died by programmed cell death.  
The transformation of undifferentiated cell population towards mature osteoblasts became fast, in 
few hours, and led to a formation of new mineralized bone in culture, without the addition of 
organic bone growth factors, such as bone morphogenetic proteins (BMP). This a very important 
advantage connect to the material. This work evidences the effective ionic dissolution products 
(Si4+ and Ca++ ions) released at slow rates from 45S5 glass. The ions produced osteostimulation 
when they are present at a particular ratio and at a particular concentration range: of 15–30 ppm 
for Si4+ and 60–90 ppm Ca2+.[8] 
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Figure3.11: Schematic of osteogenic progenitor cell cycle leading to (1) programmed cell death (apoptosis); (2) mitosis and cell 
proliferation; or (3) terminal differentiation and formation of a mineralized osteocyte (mature bone).[8] 
Figure3.11 shows biological and genetic steps in the process of cell differentiation in presence of 
ionic dissolution products. 
3.4. Mechanical properties of bioactive glasses 
The most important advantage of bioactive glasses is a fast rate of surface reaction, which leads to 
rapid tissue bonding. Their main disadvantage is the weakness and low fracture toughness due to 
amorphous glass network. Bending strength of most of the composition studied is in the range of 
40-60 MPa which make them unsuitable for load-bearing applications. Therefore this material can 
be applied as an osteointergation device as a coating, where interfacial strength between metal 
and the coating is the limiting factor, or in low loaded or compressive loaded device or in powders 
form as a bioactive phase in a composite. [9] 
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Figure 3.12: Modulus of elasticity (GPa) for prosthetic materials compared with bone[9] 
In Figure 3.12 is reported the Young modulus of different categories of biomaterial compared with 
bone. It can be seen that  the bioinert implants have the highest elastic modulus, which is very 
different from the bone one. The bioactive implants show more comparable values. The best 
choice is represented by Bioglass® and bio-composite; the last one consists in a matrix based on a 
polymer and bioactive glass particles dispersed in the matrix. These two solutions permit the best 
trade-off between the material and the young modulus similar to the bone [9]. 
3.5. Bioactive and ferrimagnetic glass ceramic 
If a ferro- or ferrimagnetic material is subjected to an alternating magnetic field, a certain amount 
of heat is generated. The heat generated per cycle depends on the hysteresis losses, which varies 
depending on the nature of ferromagnetic material and magnetic field conditions. Magnetic 
particles of glass embedded in a tumour site and placed within an oscillating magnetic field will 
heat up to a temperature dependent on the magnetic properties of the material, the strength and 
the frequency of the magnetic field, and the cooling capacity of the blood flow in the tumour site. 
Among these materials a large category of them produced heat with magnetite nucleated in the 
glass ceramic matrix. [12-18]. The mechanism of heat production depends on the size and the 
state of magnetic material.  
Bioactive and ferrimagnetic glass-ceramics are expected to be useful as thermoseeds for 
hyperthermia treatment of cancer, especially deep-seated cancers such as bone tumours. When 
they are implanted after the tumor removal, they promote the formation of bone like apatite on 
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them, and destroy cancer cells if they are located near bones. After heating, they can also 
reinforce weakened tumours bone by bonding to bone.  
Bioactive and ferrimagnetic glass are obtained by a crystallization process of iron oxide present in 
the glass composition containing Fe2+ and Fe3+ ions. Moreover they possess a good biocompatiblity  
Bretcanu et al. report the preparation and characterization of a bioactive and ferrimagnetic glass-
ceramic belong to the system SiO2–Na2O–CaO–P2O5–FeO–Fe2O3 . It is prepared by melting of 
coprecipitation-derived raw materials. The unique ceramic phase is magnetite included in an 
amorphous matrix. Magnetite crystals precipitate during cooling from melting temperature. This 
glass-ceramic would no longer require any nucleation and growth thermal treatment, since the 
maximal quantity of magnetite crystals is produced during cooling.[12] 
 
Figure 3.13: X-ray diffraction pattern (XRD) of glass ceramic[12] 
The XRD in Figure 3.13 shows the presence of a typical magnetite peaks nucleated in the 
amorphous matrix. Any other crystalline phase is reported. 
 
Figure 3.14: Scanning electron microscopy of magnetite crystals after etching[12] 
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Figure 3.14 reports a SEM image of the morphology and disposition of magnetite crystals after an 
etching of the amorphous matrix. The crystals have a columnar disposition and an octahedral 
shape.  
 
Figure 3.15: Hysteresis loops of the glass in comparison to the pure magnetite[12] 
In Figure 3.15  authors evaluate also the hysteresis loops of the glass ceramic compare with a pure 
magnetite. It can see the value of saturation magnetization is higher for magnetite  The amount of 
ferrite is higher in pure magnetite respect to the glass ceramic[12]. 
 
Figure 3.16: Results of Bioactivity test on the glass surface[12] 
Figure 3.16 reports the results of bioactivity characterization of the magnetic glass. In the figure 
3.16a several CaP precipitates are observed, figure 3.16b shows the typical morphology of HA. 
Ebisawa et al. propose a bioactive and ferrimagnetic material as a thermoseed for the treatment 
of cancer with hyperthermia. Different glass ceramics are prepared by heat treatment of base 
glasses compositions 40(FeO,Fe2O3)-6OCaO-SiO2 (wt%) with various additives at 100:3 weight 
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ratio. After that, they evaluate in vitro bone-like apatite formation in a simulated body fluid and 
the magnetic properties. .[13] 
 
Figure 3.17: hysteresis loop of CSFe+B2O3+P2O5 (CSFe+BP) glass heat treat at 1050 °C [13]  
Figure 3.17 reports the hysteresis loop of CaO-SiO2-Fe2O3-P205-B2O3 glass-ceramic (CSFe+ BP)  heat 
treated at 1050 °C. The saturation magnetization is 32 emu/g and the coercive force is 120 Oe. 
This saturation magnetization is equal to that of the CSFe glass-ceramics heat treated at 950 °C, 
whereas the coercitive force is lower (500 Oe for CSFe).The lower coercive force is attributed to 
the larger size of the magnetite crystallites. 
The results of bioactivity evidences that an addition of Na2O alone or in combination with B2O3 
and P2O5 to the basic composition produces apatite formation on the surface of the heat treated 
glass in the simulated body fluid within 10-30 days (Figure3.18). 
 
Figure3.18: Thin-film X-ray diffraction patterns of glass-ceramic CSFe + B soaked in simulated body fluid for various periods: m, 
magnetite; W, P-wollastonite; g, glassy phase.[13] 
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In another work Bretcanu et al. analyse the generation of magnetite at different melting 
temperature of glass ceramic belong to the system SiO2–Na2O–CaO–P2O5–FeO–Fe2O3. The 
material is produced using commercial reagents, melting and quenching process in the 
temperature range of 1400-1550 °C is performed.  
The magnetic properties result to be strongly influenced by glass-ceramic microstructure, which 
depends on the melting temperature. As results the increasing of melting temperature up to 1550 
°C allows the formation of the highest amount of magnetite, while the amount of hematite 
decreases (Figure 3.19). At 1500°C temperature the only crystalline phase is magnetite in an 
amorphous phase. No hematite is present at this temperature. Hematite is an unwanted phase 
because it does not possess magnetic properties since it is an antiferromagnetic material. [14] 
 
Figure 3.19: XRD patterns of ferrimagnetic glass-ceramic samples (M = magnetite, H = hematite, P = sodium calcium silicate).[14] 
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Figure3.20: Room temperature hysteresis cycles up to 12 kOe of glass-ceramic samples.[14] 
The saturation magnetisation of different tested glass ceramic varies from 18.6 to 31.5 emu/g, 
while the coercive field varies from 35 to 180 Oe.(figure 3.20) SC45-1550 is the sample with the 
high saturation magnetization value. 
 
Table 3.2:calorimetric data of glass ceramic samples[14] 
The highest power loss is obtained for sample SC45- 1500, which presents the highest hysteresis 
area, while the lower value is obtained for sample SC45-1550.(table 3.2)[14]  
A ferrimagnetic glass ceramic is proposed by Saqlain et al. belong to a system xZnO-25Fe2O3 
(40x)SiO2-25CaO-7P2O5-3Na2O, (x=4, 6, 8, 10). It is prepared by melt-quench method.  
Magnetic induction measures is developed at 500 Oe and at 440 KHz , 1 g of sample is put in the 
center of coil with 20 ml of water in plastic container. The alternate magnetic field is switch on for 
2 minutes.  
The results indicate an increase of the power loss for X8 and X10 which is in agreement with the 
increase of hysteresis area and magnetic material for the same samples.(figure 3.21)  
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Figure3.21: variation of specific power loss and temperature as a function of iron oxide content.[17] 
 
 
Figure3.22: Variation of room temperature (a) saturation magnetization, (b) coercive field, (c) remanent magnetization, and (d) 
area under the M–H loop of glassceramics as a function of iron oxide content.[17] 
Figure3.22 collects the magnetic parameters obtained from the M–H cycles of samples with 
different iron oxide content. The increase in Mr, Ms and hysteresis area, and the decrease in HC 
with an increase in iron oxide content can be attributed to increase in the amount and size of 
magnetite crystallites in the glass-ceramic samples. The area under the hysteresis loop increases 
with an increase in iron oxide content (figure. 3.22d). The area under the loop is proportional to 
the energy loss and hence the heat generated by a sample subjected to an alternating field. The 
results obtained indicate that samples with higher iron oxide concentration are capable of 
generating more heat for the same applied magnetic field. 
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Figure3.23: (a) SEM micrographs of the surfaces of glass-ceramic sample with x = 15 wt.% soaked in SBF for various days 
(magnification: 1000) and (b) EDS spectra of x = 15 wt.% soaked in SBF for 30 days.[17] 
Figure3.23 reports the SEM micrographs of glass ceramic with x = 15% of iron oxide after soaking 
in SBF for 1 to 30 days. The images clarify the increasing of calcium and phosphorus precipitation 
on the glass surfaces by increasing immersion days in SBF. EDS analysis evidences the gradual 
formation of HA since at 30 days the Ca/P ratio is quite near to 1.67 which is closed to the value of 
HA. [17] 
Leventouri et al. published a paper on a magnetic properties of a ferrimagnetic glass ceramic 
belong to the system 0,45(CaO,P2O5) (0,52-x)SiO2 xFe2O3 0.03Na2O with different heat treatments. 
Four different types of glass are prepared as a function of iron oxide content.  
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Figure 3.24: SEM images from samples of the series 20G presenting the effect of heat-treatment temperature on the 
microstructure of FBC: (a) as prepared,(b) heat-treated at 600 1C, (c) at 800 1C and (d) at 1100 1C. Bar is 2 mm.[18] 
SEM analysis evidences a strong variation in the microstructure of glass in function of the 
composition and the heat treatment. The dendritic structure of magnetite crystals is well defined 
up to 800 °C and starts to break up at 1100 °C where only a trace of dendritic phase separation is 
seen. (figure 3.24)[18] 
 
Figure 3.25: M–H plots of the samples with 5%, 10%, 15% and 20% molar fraction of Fe2O3 in the reacting oxides. The response 
in applied magnetic field H up to 4 kG is shown.[18] 
The magnetization curved are reported in Figure 3.25 as a function of iron oxide content: by 
increasing the magnetic phase the value of saturation magnetization increases.  
3.6. Structure of magnetite  
Magnetite (Fe3O4) is a combination of two iron oxides FeO and Fe2O3 in 1:1 molar fraction. 
Magnetite is a representative ferrimagnetic material. The atoms of oxygen are packed in a face 
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centered cubic lattice, in which the iron atoms, smaller than oxygen, fill the interstices. (figure 
3.26) 
 
 
Figure 3.26:Crystalline structure of magnetite: The iron in tetrahedral position are in light gray while in octahedral position are in 
dark gray, the other atoms are oxygen [10] 
In such way the oxygen around the metal ions occupying the corners of a tetrahedron or of an 
octahedron. The metal ions surrounded by an oxygen tetrahedron are in an A site and the metal 
ions surrounded by an octahedron are in a B site as it can be observed in figure 3.27. 
 
Figure3.27:Tetrahedral and octahedral cation sites in the crystal structure of magnetite (Fe3O4). In a tetrahedral site A the iron 
ion is surrounded by 4 atoms of oxygens  while in octahedral site the iron ion is surrounded by six oxygen atoms.[10] 
Magnetite has an inverse spinel structure, in which the tetrahedral sites are occupied by trivalent 
iron ions Fe3+ and the octahedral sites are shared by a 50:50 number of divalent Fe2+ and trivalent 
iron ions Fe3+. To maintain charge balance to the four oxygens (O2-), there are two Fe3+and one 
Fe2+. So all the divalent iron ions reside in the octahedral lattice sites, whereas the trivalent iron 
ions are split evenly between octahedral and tetrahedral sites. As it can be seen in figure 3.28, in 
the octahedral coordination, Fe3+and Fe2+ions are coupled ferromagnetically. The electron, whose 
spin is directed in the opposite direction of the others and coloured red, can be exchanged 
between two octahedral coordination. On the other hand, the Fe3+ ions in tetrahedral and 
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octahedral sites are coupled antiferromagnetically implying that the Fe3+ spins cancel out each 
other and thus only unpaired spins of Fe2+in octahedral coordination contribute to the 
magnetization. This magnetic moment configuration explains the ferrimagnetism seen 
in magnetite.(figure 3.28)  
 
Figure 3.28: Schematic depiction of the splitting of the 5d orbitals in octahedral and tetrahedral coordination[10] 
Magnetite is the unique crystalline phase which has magnetic properties among those presented 
in the glass-ceramics previously reported. 
3.7. Doping of glasses with antibacterial effect  
One of the main complication connected with bone diseases regards the problem of infection. The 
problem is quite diffused both when a hip prosthesis is implanted and a tumor is removed. After a 
surgical operation the area around the implant has a lower immune resistance to pathogens 
agents and for this reason it is sufficient a minimal bacterial concentration to give rise to an 
extended infection. If the problem is not considered the bacteria colonization bring to failure of 
the implant.  
Escherichia Coli and Staphylococcus aureus are two examples of bacteria stains that have a high 
adhesion capacity on a biomaterial surface, the adhesion is favoured by the presence of porosity 
and roughness that facilitate the formation of a stable bond between bacteria and the surface. 
The most common bacteria encounter in infections belong to the family of staphylococci, in 
particular they are Staphylococcus aureus (Figure 3.29) and Staphylococcus epidermidis (Figure 
3.30), the second is considered harmless lying naturally in the bacterial micro flora epidermal, 
however, in contact with biomaterials become particularly aggressive. The first can be found 
primarily on the surfaces of metal implants, while the second is typical of polymeric implant. A 
possible solution to avoid surface contamination consists in the treatment of the implanted 
material with antibiotics, but some disadvantage are connected with this prophylaxis as allergic 
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reaction, microbial flora decay and bacterial resistance. The last is the most important 
disadvantage because bacteria can develop a capacity to resist drug and so an antibiotic therapy 
can be completely ineffective as antibacterial treatment.  
 
                     Figure 3.29: Staphylococcus aureus                                            Figure 3.30: Staphylococcus epidermidis 
Many researchers tried to solve this problem studying and developing biomaterials enriched with 
some ions, which posses antibacterial properties, like silver(Ag), copper(Cu) and zinc (Zn), and a 
multiple mechanism of action. One of the most important factor is the correct regulation of 
antibacterial ionic concentration in the body in order to avoid toxic reactions for healthy cells. One 
of the most common antibacterial agent is silver, since it has a broad spectrum antibacterial 
activity and exhibits few toxicological side effect.  
3.8. Effect of silver on bacteria  
As it is explained in Figure 3.31, silver ions interact with bacteria in different ways: the ions can 
penetrate cellular membrane, interact with the DNA and stop proliferation and division of 
bacterial cells.  
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Figure 3.31:Effect of Ag ions with interact with bacteria: Mechanism of action of silver ions on bacteria. (1) The silver interacts 
with enzymes and proteins, cross the cell membrane and get into the cell. (2) interacts with DNA by inhibiting cell division. (3) is 
linked to the cell wall and inhibit the functionality of the membrane. 
3.9. Effect of copper on bacteria  
The antibacterial mechanism of copper has been attributed to the fact that copper ions are 
absorbed by the bacteria. First, the bacterial surface absorbs ions, which causes damage to the cell 
membrane and protein structure or by altering the enzymatic function; later the bacterial cells are 
immobilized due to the presence of ions  and this leads to inhibition of the replication process and 
the subsequent cell death.(figure 3.32)[28]  
 
Figure3.32: Interaction between copper and bacteria: A. The copper diffuses from the surface towards the bacteria and cause 
cellular damage B. The breakage of the cell membrane due to the copper lead to a loss of cytoplasmic contents C. The copper 
ions lead to the generation of reactive species that cause further damage D. The bacterial DNA is degraded and the cells die. [27] 
3.10. Silver ion doping techniques  
Different techniques exist to dope glasses and glass-ceramics, among them the ion-exchange 
technique and the introduction of silver during the melting and quenching process are the most 
used processes. The ion-exchange process occurs when a glass/glass-ceramic has one mobile ions 
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A species that is exposed to a source (usually molten salts bath or aqueous solution) of a second 
diffusion mobile ion B species[3,19-26] (figure 3.33). 
 
Figure 3.33:Ion exchange mechanism  
The most important parameters that govern the ion exchange process are the molar 
concentration of the molten salts, the duration of the treatment and the temperature of the 
solution. The Houndle-Walter research group reported that the interdiffusion of cations in the 
soda lime glass strongly dependent on the concentration of the non bridging  oxygen (NBO). 
Therefore, to improve the ion exchange process and to control precisely the silver distribution in 
the glass, it is necessary to understand the diffusion mechanism of silver and how it is influenced 
by the defects in the ion-exchange glass under heating and cooling. 
At temperatures of < 100°C the growth rate of total silver (oxidized and metallic forms) is low, 
then it grows rapidly until 350 °C and finally slow down. The concentration of oxidized silver 
increases a little before 300 °C and then decrease until 450°C whereas the metallic silver increases 
steadily from room temperature to 450°C. [20]  
It exists an inverse proportionality between the silver concentration in the molten salt and the 
time treatment. In fact an high silver concentration guarantees a low exposure time of the 
material while a low bath concentration implies a long ion-exchanging times. [21] 
The silver surface content is both dependent on the ion-exchanging time and on the bath 
concentration. 
 The melting and quenching technique expects the use of a silver oxide that can be added in the 
glass composition. After that all the oxides that composed glass ceramic are melted and quenched 
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and silver has modified the chemical structure of the material conferring an antibacterial 
properties. Glass/glass ceramic can be potential carriers of antibacterial ions like silver because 
these material can accommodate these ions in their structure. Moreover they can induce 
nucleation in the glass matrix and affect the local arrangement of the particles. [36].  
3.11. Copper ion doping techniques  
Even for doping a glass/glass-ceramic with copper ions different techniques can be followed  . 
Among them, ion exchange in molten salts and melting and quenching techniques are the most 
common ones. Ion exchange occurs when a monovalent alkali ions is typically replaced from ions 
present in a molten salt bath or an aqueous solution. It can be done by bringing glasses in contact 
with molten salt at a temperature below the glass transition temperature In this case univalent 
alkali ions in glass are ion-exchanged by copper ions, even if the oxidation state of copper is 
different respect to silver and it depends from the substrate composition. In fact, copper exchange 
process involves different copper states, Cu+ and Cu+2 or the possible formation of either Cu or 
Cu2O clusters critically depending on both glass and bath composition as well as on the process 
parameters [30]. 
The diffusion profile of copper inside the glass does not follow the common ordinary diffusion 
equation because of the presence of different copper oxidation states that have different 
mobility.[28] Generally, higher-valent cations are difficult to diffuse in and out though glasses 
compared to monovalent cations such as alkali [31]. 
When a monovalent copper salt is employed as an ion exchange medium the Cu+ /R+ prevails and 
Cu2+ ions which are found in glasses ion-exchange in air are formed by the oxidation of Cu+ ions 
depending on glass basicity. [28-35].  
The melting and quenching technique, even for doping with copper, expects the use of a copper 
oxide (CuO or Cu2O) that can be added in the glass or glass ceramic composition. After that, all the 
oxides are melted and quenched and copper has modified the chemical structure of the 
material.[37] 
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3.12. Antibacterial and ferrimagnetic glass-ceramics 
Some researchers developed a glass ceramic with antibacterial properties, by different chemical 
process, in order to permit the release of silver or copper ions and inhibit bacterial growth and 
proliferation.  
Sharma et al. propose a silica glass containing magnetite as mayor crystalline phase with the 
addition of silver by melt quenching tecnique, they propose a structural and magnetic 
investigations. Moreover the authors study the antimicrobial effect of the ferrimagnetic glass 
ceramic. The glass belong to the system 25SiO2–(50-x)CaO–15P2O5–8Fe2O3–2ZnO–x Ag (where x = 
0, 2 and 4 mol%). Two different heat treatment are performed: one with annealing treatment that 
produce a magnetic annealed glass ceramic (MAGC) and the other without annealing that 
produced a magnetic glass ceramic (MGC) For each heat treatment three samples are synthesized 
respect to Ag %mol. The XRD analyses (figure 3.34) evidences the presence of magnetite, 
hematite, calcium silicate and calcium phosphate as crystalline phases but not silver or silver 
compound in every glass formulations are detected.  
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Figure 3.34: XRD patterns of glass-ceramics with different Ag ion concentration (a) MGC, (b) MAGC [36] 
 
Table  3.3: Magnetic parameter estimated by M-H loops of glass-ceramics samples.[36]  
The magnetic characterization are shown in Table  3.3. Silver behaves as a nucleating agent and 
promotes nucleation and crystallization of magnetite crystals in the amorphous glass matrix. The 
fact is confirmed by increasing of saturation magnetization both on samples without annealing 
(MGC4) and with annealing treatments (MAGC0, MAGC2, MAGC4). 
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Table 3.4  Antibacterial test of glass ceramic (MGC) samples against E. Coli[36] 
Ag ions released from the glass matrix may attach to the negatively charged bacterial cell wall and 
damage it, leading to cell death. It has also been hypothesized that oxygen associates with silver 
reacts with the sulfhydryl (S-H) groups on cell wall to form R-S-S-R bonds, subsequently blocking 
cellular respiration and causing cell death. 
The antibacterial activity of Ag containing glass-ceramics is evaluated using E. coli , and the 
observations are shown in Table 3.4 . The glass-ceramic containing 4% Ag shows complete 
inhibition of bacterial growth at a concentration of 10% (w/v). However also the glass-ceramic 
containing 2% Ag shows the similar effect at 20% (w/v).[36] 
Another group of researchers present a study regard the influence of copper oxide (CuO) on a 
magnetic properties of glass ceramic belongs to a system of Fe2O3·CaO·ZnO·SiO2.syntetized with 
melt and quenching technique. They evaluated phase separation, microstructure, amount and 
crystalline size of magnetite after controlled crystallization by gradual addition of CuO to the glass 
composition and with different heat treatments. No antibacterial tests were performed.  
The XRD performed after a melting temperature between 1450°C and 1455°C as a function of 
copper oxide reviled the presence of magnetite as the unique crystalline phase up to 5 mg of CuO 
present in the sample. Increasing the amount of CuO at 10g, 20g and 30g in the glass ceramic 
compared cuprite (Cu2O) and delaffosite (CuFeO2) as further crystalline phases . From reference 
pattern the magnetite peaks in these spectra resulted a little bit shifted.  
Other samples underwent an heat treatment at 800 °C for 2 hours or 8 hours and a new M2 
magnetite phase was detected. Heat treatments favours the crystallization of cuprite (Cu2O) and 
delaffosite (CuFe2O) with the increasing of CuO, reducing the formation of magnetite.  
Analysing the crystallography parameters, the replacement of Fe by Cu results in a decrease of the 
cubic parameter. The a-axis shrinks due to the smaller ionic radius of Cu2+ (0.57 Å) cations, which 
substitute Fe3+ (0.65 Å). 
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The increase of Cu amount , heat treatment applied and substitution of Fe ions by Cu ions imply an 
increase in crystallized magnetite but not in crystalline size .  
 
Table 3.5: Magnetic parameter of some selective samples[37] 
The magnetic characterization are reported in table 3.5. The samples without heat treatment 
show maximum saturation magnetization.[37] Adding CuO > 10 g/100 batch there is a separation 
of large amount of delaffosite (CuFeO2) phase causes decreasing in the amount of Fe ions present 
for magnetite crystallization, so, Ms is decreased in 30 Cu than in 5 Cu (800 °C/8 h) sample. The 
formation of delaffosite reduces the magnetic signal because the iron ions are not in a spinel 
structure.  
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4.1. Composite bone cements 
In this chapter it is presented the state of the art of the ferrimagnetic bone cement for the care of 
bone tumor using magnetic hyperthermia. In these composites cements a magnetic phase is 
embedded in a polymeric matrix in order to develop a cement that can be used as bone filler or 
for the fixation of prosthetic devices.[1-8] 
4.1.1. Magnetic bone cements 
A poly-methyl-methacrylate bone cement loaded with Fe3O4 particles is proposed by Kawashita et 
al. and the evaluation of the composite properties is performed[1]. Magnetite particles have an 
average particle size of 5 µm, while spherical PMMA powder has an average molecular weight of 
270 kDa. PMMA powder/MMA liquid weight ratio is 2/3. Three different cement formulations are 
synthesized with 40 %wt (M-40c),50%wt (M50c),60 %wt (M60c) of magnetite micro particles 
added to a polymer matrix.  
 
Figure 4.1: Changes in the temperature of the cement samples during the setting reaction.[1] 
The reduction of maximum polymerization temperature occurred with an increased of magnetic 
microparticles (figure 4.1). 
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Figure4.2:SEM analysis of cross- sectional areas of the cement samples.[1] 
The SEM analysis evidences no chemical interaction between PMMA and magnetic microparticles 
that are dispersed uniformly in the polymer .(figure 4.2) 
 
Figure 4.3: Magnetization curves of Fe3O4 powder and sample M-50c and M-40c under magnetic fields of 10 kOe 
Figure 4.3 reports saturation magnetization curves of Fe3O4 powder and samples M-40c and M-50c 
in magnetic fields of 10 kOe, It can be seen in figure 4.3 that the Fe3O4 powder is ferromagnetic, 
with a saturation magnetization value of Ms = 83 emu g
-1 and a coercive force of Hc = 141 Oe. This 
value of Ms is close to that of bulk magnetite Ms = 89– 95 emu g
-1. Figure 4.3 also shows that 
sample M-40c have an Ms of 35 emu g
-1 and an Hc of 139 Oe, while sample M-50c has an Ms of 46 
emu g-1 and an Hc of 143 Oe 
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Figure4.4: Calorimetric curve of different samples at different alternating magnetic field of 120 and 300 Oe at 100 kHz[1] 
The surface temperature of the control sample (PMMAc) remains constant in a magnetic field of 
300 Oe, whereas the surface temperature of samples M-40c and M-50c increases over 70 °C 
within a very fast time with the same magnetic field. While using a magnetic field of 120 Oe, the 
surface temperature of samples M-40c and M-50c reached around 40 and 48 °C within a period of 
about 8 min (figure 4.4). These last temperatures are in agreement with the hyperthermic 
treatment . 
Li et al. propose [2] a PMMA bone cement loaded with different size of Fe3O4 nanoparticles (300, 
35, 11 nm). They assess mechanical strength, biocompatibility and heating capability. The heat 
generation strongly depends on the dimension of the magnetic nanoparticles and from applied 
magnetic field and frequency.  
 
Figure4.5: Compression strength without and with magnetite nanoparticles.[2] 
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The inclusions of magnetic nanoparticles into the PMMA matrix by 30% wt do not decrease 
compression strength (figure 4.5). 
 
 
Figure4.6: The total DNA concentration of Rat-1 fibroblast cells adhered on cement discs. Data are shown as the mean 6 SD 
(n ¼ 5). p > 0.05 indicates no significant increases in the DNA concentration measured until day 7 of the culture for both 
types of cement discs.[2] 
From a biological point of view, the DNA analysis evidences no inhibition effect on cell 
proliferation connected with magnetite nanoparticles.(figure 4.6)[2] 
Tang et al report the synthesis of Fe3O4 nanoparticles by chemical co-precipitation method. After 
that the nanoparticles are embedded into PMMA matrix and four type of cement are prepared 
(table 4.1) [3]. 
 
Table 4.1: Composition of PMMA based cements containg Fe3O4 powders  
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Figure 4.7: Surface temperature change of PMMAc, PF-10 (A), PF-20 (B) in the AMF of 100 Gs, 125 Gs,150 Gs at a frequency of 
500 kHz[3] 
The in vitro heat generation is shown in figure 4.7. In the first graph is reported the sample with 
the lowest amount of magnetite nanoparticles at three different applied magnetic field. The best 
result is obtained at 100 Gs after 600 s where the sample reaches the necessary superficial 
temperature for cells apoptosis (43°C-45°C) In figure 4.7b is reported the heating capability of PF-
20 sample. It can be noticed how the temperatures reached at three applied magnetic field are 
too high respect to the hyperthemic treatment.[3] 
A clinical study on a treatment of bone metastasis  is developed and reported by Matsumine et 
al.[4] They divide the patients in three groups: patients who undergo to hyperthermia treatment 
with a magnetic material (HT group). Two control group: one who undergo to palliative operation 
(OP group) without postoperative radiotherapy and another who undergo an operation in 
combination with postoperative radiotherapy (OP+RT group). 
The HT group is divided into two sub-categories: eight patients with a very critical tumor situation, 
are treated with an intramedullary nail reinforcement without any stripping of metastatic lesion. 
Eight patients, who are expected to have a better clinical situation, after lesion removing, followed 
a prosthetic substitution or reinforcement with a metal intramedullary nail or plate (n = 7). 
Calcium phosphate cement (CPC) containing Fe3O4 powders is implanted into the cavity.[4] 
An alternating electromagnetic field generator is developed with 1.5 MHz in fixed frequency. The 
intensity of the magnetic field is modulated in order to obtain a temperature of around 43°C at the 
interface bone-implant. Hyperthermic treatment is performed postoperatively on days 
8,10,12,15,17, 19,22,24,26,and 29. The exposure time is 15 min per day. 
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Table4.2: Radiographic outcomes[4] 
About 50% of patient treated with hyperthermia improved their quality of life.(table 4.2)  
 
Figure4.8: 63-year-old patient with metastatic lung cancer to the humerus (arrow). (b) After curettage of the lesion followed 
by reinforcement with intramedullary  wire, CPC containing Fe3O4 was implanted into the cavity. (c) At 6 months after 
undergoing hyperthermia, massive new bone formation has become visible (triangle) [8] 
Figure 4.8 reports a solution in the treatment of bone metastasis: the patient presented cancer 
formation in the homerus (see fig 4.8a). The surgical operation provides the implant of a metallic 
reinforcement with the addition of CPC with magnetite (see fig 4.8b). The heat is monitored at 
surface of a cortical bone using a thermometer.[4] After 6 mouth of hyperthermia treatment a 
new massive bone formation is seen in the radiograph(figure 4.8c).  
4.1.2. Magnetic and bioactive bone cements 
Takegami et al. propose a bone cement containing silica particles and magnetite powder 
embedded in a bis-GMA based resin composed of bis-a-glycidylmethacrylate and triethylene-glycol 
dimeth-acrylate.(figure 4.9). The average particle size of the magnetic powders is 13 µm and for 
silica glass powder is 3 µm[5] 
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Figure 4.9: Ferromagnetic bone cement. Filler: magnetite powder and silica glass powder. Resin: bis-a-glycidymethacrylate and 
triethylene glycol dimethacrylate[5] 
As previously mentioned, one of the most important properties of this type of magnetic material is 
the ability to generate heat under stimulating of an alternate magnetic field. The energy 
generated from hysteresis cycle is transformed into heat with a consequently increasing of 
temperature of the surrounding tissues.[5] 
The heat generation of ferrimagnetic bone cement is evaluated as a function of the amount of 
magnetite, volume of the cement and intensity of magnetic field.  
 
Figure 4.10: (A) The position of sensors in the rabbit tibiae. (B) Time/temperature curve. a, the surface on the cement; b–d, the 
interface between bone and muscle; e, medullary canal[5] 
Figure 4.10 shows the results of distribution of heat into the bone. The cement is injected in a 
rabbit tibiae and five temperature probes are located in different areas of the bone. The sensors 
are at the surface of the cement (a), at the interface between bone and muscles (b-d) and in the 
medullary canal (e). The results evidence a correlation between the position of the sensor an the 
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temperatures measures. For e sensor which is the farthest from the heat source the temperature 
profile remain flat at 37°C.[5]  
 
Figure 4.11:  (A) Relationship between temperature and content of magnetite with a magnetic field of 80 Oe) . (B) Relationship 
between temperature and volume. Volume is shown as the height of the block (base of block, 20x20 mm; content of magnetite, 
40%; magnetic field, 100 Oe) . (C) Relationship between temperature and intensity of magnetic field (block, 20x 20 x 5 mm; 
content of magnetite, 40%) .[5] 
Figure 4.11 shows the temperature increase as a function of content of magnetite, volume of the 
cement and intensity of the magnetic field.  
For the control of the hyperthermia treatment exists an inverse correlation with time and 
temperature, if high temperature, about 50°C, are obtained the heating will maintained for few 
minutes .If temperature reaches 43°C it can heat even for 1 hour in order to avoid local 
recurrence. [5] 
Other authors realize an electromagnetic field generator at a fixed frequency of 1,5 MHz[6]. They 
synthesize a bone cement loaded with a glass ceramic that is partially substituted by magnetite 
Fe3O4 powder.  
 
Figure 4.12: Three different behaviour of a bone tumor: left panel show a bone tumor untreated, in the middle a bone tumor 
with an injection of magnetic material an on the right panel a double effect of a magnetic material with the stimulation of an 
electromagnetic field.[6] 
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They introduce tumor cells into a tibia of rabbits and evaluate the status of bone by X-ray 
radiographies in three different situations: without cement implant, with magnetic cement and 
with cement + hyperthermia treatment. In the first situation the tumor proliferates and massive 
bone destruction is observed. Instead when magnetic material and an electromagnetic field are 
applied for 50 minutes the bone tumor is sensibly reduced as it can be observed in figure 4.12. The 
cement is composed by 60% wt. of magnetite.[6] 
Portela et al. proposed a ferrimagnetic silicate cement (FC) with high amount of iron oxide, with 
the following oxides chemical composition (%wt) : 10 SiO2, 2 Al2O3, 52 Fe2O3, 0.6 MgO, 33 CaO, 
(SO3+K2O) R. The maximum powder/water combination ratio (3:2) is used. Paste flows and the 
product is able to be injected.[7]  
 
Figure 4.13:Ferrimagnetic cement immersed in normal SBF. A Precipitates covering the initial surface . b The precipitation of Ca 
and Mg phospjate compound is detected. All the initial cement peaks of Si and Fe decreased and a high peak of P can be 
observed[7] 
Figure 4.13 reports the results of bioactivity test, as it can be noticed a large layer of apatite 
precipitates on cement surface after the immersion in SBF for 4 days. In the EDS spectrum the Ca 
and P peaks are higher than silica and iron, demonstrating the precipitation of precipitates rich in 
Ca and P.[7] 
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They test the injectability of the cement evaluated as the ratio between volume of paste ejected 
from a syringe respect to a total volume of paste before ejection. After a determination of a 
suitable powder liquid ratio an injectability value is found during 5 min after mixing.[7]  
Kusaka et al. propose a cement composed by a a resin (bis-a-glycidymethacrylate) and magnetite 
and silica powders as filler phase. They introduce a tumoral mass into a hole create into a tibia of a 
rabbit. After seven days they open the wound, tumor is removed and the defect is filled with 
cement. Nine rabbits are exposed to a magnetic field for 50 min with an hyperthermic treatment 
(HT group) and 9 animals are not exposed to the magnetic field (non-HT group). After the animals 
sacrifice the maximum circumference of the skinned leg is measured to record tumor growth.[8] 
 
Figure 4.14: Maximum circumference of the skinned leg as a function of time after inoculation of VX2 tumor in hyperthermic 
therapy (HT) group (black circles) and non-HT group (gray circles). A significant difference is shown between groups (P < 0.05)[8] 
In figure 4.14 back dots are values of leg diameter subject to an hyperthermic treatment while the 
gray dots represented the non HT group as a function of time.[8] Size of leg do not change with 
time for treated rabbit and remain between 6-8 cm while measure of non-treated legs increase 
over 8 cm. The maximum diameter is 16 cm. [8] The hyperthermic treatment stabilized the tumor 
and do not induce its proliferation  
The object of the present research activity regards an experimental study on a new magnetic and 
bioactive bone cement .  
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The European Society for Hyperthermic Oncology (ESHO) officially recognizes  the hyperthermia 
treatment in oncology as “the therapy which uses the generation of a higher temperature at a 
tumor-involved region of the body”. This approach uses a variety of temperature ranges (from 39 
– 40 °C up to 80 – 90 °C) and, accordingly, a great number of techniques to induce those 
temperatures under well-controlled conditions. 
During the past, physicians have tried to utilize artificial temperature elevations for the treatment 
of various diseases, included tumor diseases, but due to the complexity of interactions, the 
attempts were often too unspecific to be really successful. 
Today it is widely recognized that a large number of intracellular processes exist with a specific 
temperature-dependent behaviour. 
For example, there is evidence of: 
 Enhancement of anti-tumor effects of various drugs and radiation (typically in the range 
40-43°C)  
 Induction of immunological processes (39 – 41 °C, fever range) 
  Induction of gene expression and protein synthesis (40 – 42 °C) 
 Influencing the tumor microenvironment in a way that makes the tumor better accessible 
for some therapies. 
The most beneficial contribution of hyperthermia for oncological treatments is based on the 
enhancement of the effectiveness of other treatments (radiotherapy, chemotherapy, radio 
chemotherapy, gene therapy, immune therapy etc) without additional toxicity.  
Taking into account the state of the art regarding the problem of bone tumours, the materials 
developed for their care and the techniques for their application, in the following chapters the 
new approach developed during my PhD research activity will be presented. 
The research is intended to study and develop an innovative multifunctional composite material 
useful for the treatment of the primary and secondary bone tumours, by means of non-invasive 
hyperthermia, and for the prevention of the associated complications, such as osteoporosis, 
osteomyelitis and inflammation. 
The principal aim of the research was to develop a composite bone cement which possess at the 
same time biocompatibility, bioactivity, ferromagnetic properties and suitable mechanical 
properties. A further aim, developed in the last part of the experimental work, was the 
modification of one constituent of the bone cement with antibacterial ions.    
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The developed material is a composite PMMA-based bone cement. The polymeric matrix is a 
commercial cement produced and distributed by Haeraus Medical (Germany). The added phase is 
a glass ceramic powder developed and realized in the laboratory of the Department of Applied 
Science and technology (DISAT) at Politecnico di Torino. The glass ceramic belongs to a system 
Na2O–CaO–SiO2–P2O5–FeO–Fe2O3. 
The proposed material possess several innovative characteristics compared to previously 
developed formulations, both in academia and industry, and have strong potential for the 
treatment of the primary and secondary bone tumours. It can be used as fillers for bone cavities, 
even of complex shaped, promises faster restoration of functionality, reduces the frequency of 
infection and provides an opportunity to apply hyper-thermal therapy, without additional surgical 
operation, in order to kill the tumor cells, which were not surgically removed or those formed 
during an eventual relapse 
The innovation concerns the development of the glass ceramic to be added to the polymeric 
matrix, which can contribute to the resolution of three important problems connected with bone 
tumor: poor mechanical and biological interaction between bone and implant, poor efficiency of 
radio- and chemotherapy as well as other hyperthermia treatments of bone tumor (ultrasound or 
microwave) and  bacteria colonisations.  The osteointegration of the implant is imparted by the 
glass-ceramic composition. Ferrimagnetic properties confer the ability of generate heat under an 
alternate magnetic field in order to kill tumor cells that can appear after implantation. 
Antibacterial properties conferred by the chemical modification of the glass-ceramic with silver 
and copper ions are aimed to  avoid or reduce osteomyelitis, which are often associated to bone 
tumours surgery.  The peculiarity and the surplus value of the proposed material, respect to the 
actual commercial and experimental formulations, is to simultaneously perform several functions 
by the addition of a single dispersed phase to the polymeric matrix. 
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5.1. Design of the Research  
The research was designed to be developed in sequential steps in order to obtain progressive 
confirmation of the feasibility of the main aim.  
First step 
In the first step synthesis and characterization of the bioactive and ferromagnetic glass ceramic 
(identified in the following with the abbreviation SC45) were performed: 
  Optimization of melting parameter in order to obtain a high degree of crystallized 
magnetite into the glass-ceramic 
 Morphological and compositional analysis with Scanning Electron Microscopy (SEM) and 
energy dispersion spectroscopy (EDS) 
 Study of the crystalline phase with X-ray diffraction pattern (XRD) 
 Estimation of % wt. of formed magnetite with different methods based on : 
o  Calorimetric measurements  
o  XRD analysis with an internal standard calibration curve 
o  Quasi static electro-magnetic tests with hysteresis loops 
 Elemental mapping of chemical atomic compound  
Second step 
In the second step the synthesis and characterization of the composite bone cements was 
performed, by adding different %wt ( 10%,15%, 20%) of bioactive and ferrimagnetic glass-ceramic 
to a commercial PMMA matrix (identified in the following with the abbreviation P10-P15-P20) by: 
 Morphological and Compositional evaluations with SEM and EDS 
 Mechanical tests: 
o Uniaxial Compression test according ISO 5822-2002 standard 
o Four point bending test according ISO 5822-2002 standard 
 Analysis of surface fractures after bending tests 
 Setting time evaluation according ISO 5822-2002 standard 
 Calorimetric measurement for the quantification of heat generation 
  Analysis of the glass-ceramic and porosity distribution  with Micro Computed Tomography 
(MicroCT)  
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 Hysteresis cycles on both the SC45 and the composites with high and low external 
magnetic field  
 Impedance measurements for the evaluation of dielectric and magnetic permittivity 
Third step 
In the third step an in vitro characterization of the composites was performed by: 
 Bioactivity tests after soaking in SBF for one month  
 Iron leaching tests  
 Cytocompatibility tests 
Fourth step 
In the fourth step the effect of heating on both health and tumoral cells up to 40- 43 °C by an 
external alternating magnetic field was evaluated. 
Fifth step 
In order to add antibacterial properties to the material, the SC45 glass-ceramic was doped with 
silver and copper ions with two different methods: 
 Melting and Quenching: 
o 3% wt of Ag2O was added in the glass composition, identified as SC45 3Ag 
o 5% wt of CuO was added in the glass composition, identified as SC45 5Cu 
With the follow characterizations: 
o XRD analysis 
o SEM and EDS analysis  
o Calorimetric measures 
o Hysteresis cycles at low and high external magnetic field  
o Antibacterial tests with inhibition halo  
 Molten salts ion exchange 
The synthesis considered three different molar concentrations of silver and copper used for 
doping SC45: 
o Na/Ag = 2000 [mol/mol], identified as SC45 Ag2000 
o Na/Ag = 200   [mol/mol], identified as SC45 Ag200 
o Na/Ag = 20     [mol/mol], identified as SC45 Ag20 
o Na/Cu= 2000  [mol/mol], identified as SC45 Cu2000 
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o Na/Cu= 200    [mol/mol], identified as SC45 Cu200 
o Na/Cu= 20      [mol/mol], identified as SC45 Cu20 
 
With the follows characterizations: 
o XRD analysis 
o SEM and EDS analysis  
o Calorimetric measures 
o Antibacterial tests with inhibition halo  
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5.1.1. Production of the glass-ceramic (SC 45) 
The chemical composition of SC 45 is reported in table 5.1. It contains SiO2, CaO, Na2O and P2O5 in 
the same ratio as the bioactive glass 45S5 (Bioglass®) [1], with the addition of two different types 
of iron oxides. The amounts of two iron oxides were chosen to obtain the formation of a high 
amount of magnetite (ideally the theoretical value of 45 wt%). This value was optimized by 
previous studies as a good trade-off between heat capacity generation and bioactivity of the 
material [2-4]. Magnetite is a ceramic phase that confers a ferrimagnetic behaviour to a glass. The 
chemical composition of the glass ceramic is reported in table 5.1. 
 
Table 5.1: Glass ceramic composition (%wt) 
For the synthesis of the glass-ceramic high purity raw materials were used: Na2CO3 (Sigma-Aldrich) 
with a purity ≥99,5%, CaCO3 (Sigma-Aldrich) with a purity ≥99, SiO2 (Sigma-Aldrich) with a purity 
≥99%, Ca3(PO4)2 (Fluka) with a purity ≥96%, FeSO4*7H2O (Sigma-Aldrich) with a purity ≥99% and 
Fe2O3 (Sigma-Aldrich) with a purity ≥99%. Each component was weighted and, before melting, the 
powder reagents were mixed in a flask on a mixing roller for 15 minutes. 
As reported in Bretcanu et al.,[2] the reactants were melted in a platinum crucible at 1550°C inside 
a high temperature furnace (Nabertherm - Carbolite 1800) for 25 min, using a heating rate of 
10°C/min. The melt was cooled at room temperature in air and poured into a brass mold, 
obtaining partially crystallized (glass-ceramic) bulk samples. As reported in [2], the value of 
melting point permitted a high conversion of iron oxide in magnetite. The obtained bulk samples 
were polished with SiC abrasive paper P320 and P600 in order to remove the thin oxide layer that 
often formed on their surface.  
The bulk was milled and sieved to reach a grain size below 20 m. The milling process was 
performed with a Planetary Ball Mill (Vibratory Micro Mill PULVERISETTE 0 Fritsch) in a Zirconia jar 
and the milling conditions were optimized in order to minimize the production of particles of grain 
size < 5 m (checked by SEM analysis). Specific Particle size was chosen because previous studies 
demonstrated that a particle size <5 m is characterized by high agglomeration phenomena and, 
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on the contrary, too many larger particles can cause a decrease in the mechanical properties of 
the final sample.  
 
Figure 5.1: Synthesis steps for the glass ceramic production with melting and quenching technique : Reagents in a platinum 
crucible(a), pouring on plate (b), milling (c1) and sieving up with 20 micron mesh sieve (c2), ferrimagnetic glass ceramic powder < 
20 μm (d). 
Figure 5.1 shows a summary of all the SC45 glass ceramic production steps. 
5.1.2. Production of the composite (P10, P15, P20) 
The composite cements were synthesized using a commercial Poly methyl methacrylate (PMMA)-
based cement with medium viscosity (Palamed®, produced by Heraeus Kulzer S.r.l.) containing 
zirconium dioxide (ZrO2) as radio-opaque phase. The Palamed® cement is commercialized in a kit 
with one packet of a solid phase containing poly-(methylacrylate, methylmethacrylate), ZrO2, 
benzoylperoxide, colorant E141 and one ampoule of liquid containing methyl methacrylate, N,N-
dimethyl-p-toluidine, hydroquinone, colorant E141. 
The commercial cement was prepared by manually mixing the polymer powder component with 
the liquid monomer component. A ductile dough was formed, which cured within a few minutes. 
The ratio of PMMA powder/ MMA liquid used was 2 g/ml as specified in the product technical 
data sheet. 
Composite bone cements were produced adding different wt% of glass-ceramic (10, 15, 20 wt%) 
using a solid phase (PMMA+ SC 45)/liquid phase (MMA) ratio of 2 g/ml and these were identified 
as P10, P15 and P20, while the commercial formulation was named control. 
The mixed powders were put in an orbital shaker for at least one hour, in order to obtain a good 
level of homogenization. Subsequently, they were mixed with the liquid monomer for 30 s to start 
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the polymerization reaction. The dough was put into a polished aluminum mold (100x100x5mm 
with 25 holes of 10mm in diameter) and after hardening the samples were extruded. 
 
Figure 5.2: Synthesis steps of magnetic bone cement production: manual mixing with PMMA/MMA + SC45 < 20 μm in different 
% wt proportion (10-15-20) (e-f). After setting and extrusion from mould , different samples are prepared for different test: 
compression test (h), bioactivity and calorimetric tests (g), four point bending test (i). 
As for the glass ceramic, figure 5.2 shows the composite bone cement synthesis process and all 
different size and dimension of the prepared samples. 
It was chosen to start with three different synthesis of composite bone cement in order to 
evaluate which formulation could be the best trade-off among all the next characterizations. 
5.1.3. Glass ceramic characterizations  
The complete structural, morphological-compositional and in vitro characterization of the glass-
ceramic was performed in previous works.[2,6] Here the attention was focused on the 
identification of the real magnetite percentage in the glass-ceramic, as already done on similar 
materials obtained by co-precipitation derived precursors.[7] 
In order to identify the real wt% of magnetite inside the residual amorphous glass matrix three 
different methods were used: X-ray diffraction (XRD), calorimetric tests and saturation 
magnetization of the hysteresis cycle. 
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5.1.4. X-ray diffraction 
The first method consists in the realization of a calibration curve calculated as an interpolation of 
the single points using fluorite (CaF2) as an internal standard. The single points were obtained by 
performing the XRD analyses of samples containing 0%, 25%, 50%, 75%, 100% of pure magnetite 
with 20% wt of CaF2, mixed in an amorphous phase (powders) of Bioglass® 45S5, simulating the 
composition of the magnetic glass-ceramic synthetized in this work (the values are the mean of 
three measurements). The obtained diffraction data patterns of the mixtures were fitted and the 
intensity ratio between the (311) magnetite diffraction line and (111) fluorite line was determined 
and plotted against the weight fraction of magnetite. The ratio increases with the increasing % wt 
of pure magnetite powder with respect to a constant % wt of CaF2. The same amount of CaF2 was 
added to the SC 45 sample and XRD analysis was performed. The value is a mean of three 
measurements. 
The crystalline phase in the glass-ceramic was analysed by Philips X’Pert diffractometer with CuKa 
radiation, using a step of 0,02 (2) with a scan step time of 1 s. The diffraction lines were identified 
using the ‘‘X’Pert High Score’’ program, with the PCPDFWIN database (2002 JCPDS- International 
Centre for Diffraction Data). The profile fitting of the diffraction pattern was performed by using 
the same software in order to determine the crystalline phase. 
5.1.5. Calorimetric test 
The second method was based on a calibration curve obtained by calorimetric measurements. 
The single points were obtained performing heating cycle of samples containing 0%, 25%, 50%, 
75%, 100% of pure magnetite mixed in an amorphous phase (powders) of bioactive glass 45S5, 
simulating the magnetic glass-ceramic composite. The cycle was performed with an induction 
furnace, Egma 6, product by FELMI S.r.l at 48mT (1 kW) for a constant time of 3 min and 
registering the initial and final temperature before and after the heating with a digital 
thermocouple (Datalogger Tersid). All the measurements were performed in 10 ml of distilled 
water. 
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5.1.6. Saturation magnetization 
The third method was based on the evaluation of the hysteresis loops of the glass ceramic and the 
pure magnetite. Then the %wt of magnetite crystalized into the amorphous glass network was 
calculated as the ratio between the saturation magnetization value of SC45 with respect to a 
values of pure magnetite with the following formula:  
100*
45
%
43OMsFe
MsSC
Magnetite  (5.1.1) 
Where 
Ms SC45 = Saturation magnetization at 800 kA/m of the SC45 
Ms Fe3O4 = Saturation magnetization at 800 kA/m of the pure magnetite  
The particles of magnetite (Sigma-Aldrich) have a dimension < 5 m. 
Hysteresis cycles were measured up to 800 kA/m by means of a DC magnetometer/ AC 
susceptometer (Lakeshore 7225) equipped with a Cryogen-Free Magnet at room temperature in 
quasi static condition. At 800 kA/m the hysteresis cycles both of SC45 and of the pure magnetite 
were already closed and so it was possible to determine the saturation magnetization values. 
5.1.7. Composite bone cement characterizations 
5.1.8. Morphological and compositional characterization 
 A morphological and compositional analysis was developed on composite bone cements (P10, P15 
and P20) by SEM-EDS techniques in order to investigate the glass ceramic dispersion in the PMMA 
matrix. The analyses were performed both on the surface and on the section of the samples.  
5.1.9. Calorimetric tests 
In order to estimate the heating ability of the composite bone cements, they were subjected to 
calorimetric measurements using an alternate magnetic field and detecting the increase in 
temperature of a volume of water containing the samples. The test was developed using a 
magnetic induction furnace Egma 6 (Felmi S.r.l) generating a magnetic field intensity in the range 
0– 118 mT at fixed working frequency of 220 kHz. For each cement formulation (P10, P15, P20) 
two composite samples were put inside a glass test tube with a diameter of 10 mm and a height of 
160 mm. 
Materials and Methods 
 
103 
Matteo Bruno 
 
The samples were immersed in 10 ml of distilled water and the initial temperature T in was 
measured with a thermocouple. Then, the tube containing the samples was positioned in the 
middle of the coils of the inductor. A magnetic induction of 48mT was applied and the final 
temperature Tfin was measured after 2, 4, 6, 8, 10 and 12 min. After each measurement the 
samples were cooled in air at room temperature (figure 5.3). 
The same test was repeated three times for each cement formulation to minimize the data 
scattering.  
 
Figure 5.3: Calorimetric set-up for heating measures 
The measured temperature as a function of the field application is used to calculate the specific 
power generated by magnetic hysteresis loss by applying the heat diffusion equation[8]: 
 
                   
where 
 The first term of the equation concerns the heating term of overall system. 
 The second term is the power generated by the sample due to magnetic hysteresis 
 The third term is the thermal dissipation toward the external environment. 
The solution of this equation, assuming an isothermal behaviour of the system (the same 
temperature of the components subject to heating) and the temperature of beginning transitional 
(Tin) equal to the room temperature (Tr), is:  
(5.1.2) 
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                                                   (5.1.3) 
that solved as a function of W becomes: 
                                                        (5.1.4)    
 
where: 
W= thermal generated power [Watt], the specific power [W/ g] is obtained by dividing W by the  
weight of the sample under examination. 
T = T - Tr : increase of water temperature in the period of field supply [°C] 
t = exposure time to magnetic field supply [s] 
M = mass of all physical component of the system [kg] 
Cp = specific heat [J/(kg °C)] 
M*Cp = MC = thermal capability of the system, intended as the sum of the thermal capacity of the 
components subject to heat [J/°C] calculated as: 
MC = m water* cp water + m sample* cp sample + m glass tube test*cp glass tube test (5.1.5) 
where  
mi is the mass of the i-component  
cpi is the specific heat of related material, for the composite cement was assumed the specific heat 
of PMMA. 
KS = global transmittance calculated as: 
K = transmittance surface towards the ambient [W/(m2 °C)] 
S = exchange surface of the heat towards the ambient [m2] 
The data T and t are subjected to experimental survey, MC and S are calculated on the basis of 
the physical properties of the materials and the geometry of the system. K was estimated on the 
basis of data available in the literature [8] and considered not dependent on the surface 
temperature because of its reduced range variation. 
S = the outer surface of the tube (limited to the free surface of the water) = 0,005 [m2] 
K = transmittance of a vertical tube in still air at a mean temperature of 40 ° C = 13 [W/m2 ° C] 
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Having defined the constant terms, MC and KS, it is possible to construct a temperature versus 
time curve whose comparison with experimental measurements allows the evaluation of the 
better fitting function that represents the thermal phenomenon. 
5.1.9.1. Experimental model with thermal insulator  
In order to better quantify the temperature increase of a precise volume of water and specific 
power losses, a similar set up was optimized by the addition of a dark thermal insulator around 
the test tube in order to reduce the heat dispersion toward the environment and for a better 
quantification of all heat generated from three different sample formulations (P10, P15, P20) .  
 
Figure 5.4: Calorimetric set up with a foam polyethylene as a  thermal insulator 
The system is composed of three samples, 26 ml of distillate water, the glass test tube with a 
diameter of 10 mm and an height of 160mm, a foam polyethylene thermal insulator (λ = 0,038 
W/(m*K)) (see figure 5.4). The test was performed using two magnetic induction furnaces Egma 6 
(Felmi S.r.l) generating a power up to 6 kW (39 mT) with a fixed working frequency of 220 kHz and 
Egma 30 (Felmi S.r.l) with a power generation up to 18 kW (132 kA/m) with a fixed frequency of 
200 kHz . The measure of temperature was performed by a digital thermocouple (Datalogger 
Tersid S.p.A). The initial temperature (Tin) and  final temperature (Tfin) was recorded at t = 0 min, t 
= 5 min, t = 10 min switching off the magnetic field for 1 minute between one time and another. 
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The proposed experimental model is based on the quantification of the energy storage in the 
different heated elements (sample, water, test tube) during the time of field application and on 
the theoretical evaluation of dispersions towards the environment. 
The irradiation contribution was neglected because the thermal insulator temperature is close to 
the environment one.  
Each component had the ability to store a specific amount of heat that has been quantified with 
the formula:  
Est= ∑(mi*cpi)*T (2) [8] (5.1.6) 
Est depends on the heat capacity (cpi), the mass of the element (mi) and the delta of temperatures 
between the initial and final heating period. 
The dispersion term is quantified as the heat dispersion per conduction per unit heating time: 
Ed = U*t* (Tmax - Tamb) (3) [8] (5.1.7) 
U transmittance coefficient between the test tube and the thermal insulator (J/(s*°C)) 
t heating time (s) 
Tmax medium heating temperature of the water (°C) 
Tamb room temperature (°C) 
The total amount of heat (energy stored + dispersion) is divided by the maximum heating time (10 
min) and by the sample mass in order to obtain a specific power loss. The measurements were 
performed in duplicate. 
5.1.10. Magnetic hysteresis measurements  
Magnetic properties are investigated with a DC magnetometer/ AC susceptometer (Lakeshore 
7225) equipped with a Cryogen-Free Magnet Frumagnet at room temperature in quasi static 
condition.  
In particular hysteresis cycle measurements were performed both on the SC45 and on the P10, 
P15, P20 composite cements samples into two different magnetic field ranges: up to 800 kA/m 
(high field) to study the magnetic characteristics of the materials and up to 34 kA/m (low field) in 
order to work  in a magnetic field range that can be used in clinical laboratories [5]. This test 
allowed the evaluation of the energy generation in one hysteresis cycle 
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5.1.11. Impedance measurements  
These types of electromagnetic measurements had the aim of evaluation of the response of the 
material to an electro-magnetic stimulation.  
The impedance is a physical vector which represents the opposition force to a passage of an 
alternate electric current in a bipol . It can be expressed as a ratio between the phasor of the 
voltage and the phasor of current. It is indicated with Z and it is measured in ohm [Ω]. 
The impedance is described by a complex number, real part represents dissipative phenomenon 
which correspond to an electric resistance R while the imaginary part indicates reactance X, 
associated to energy storage phenomena: 
jXR
I
V
Z      (5.1.8) 
For a purely inductive or capacitive circuit, the impedance is thus reduced to pure inductive or 
capacitive reactance. The reactance of a capacitor and an inductor in series is the algebraic sum of 
their reactance. [10] 
LC XXX      (5.1.9) 
5.1.11.1.  Dielectric permittivity measurement 
For this measurement the polymer-based material and the composites were considered to be 
dielectrics between two metal copper armatures. They were excited by a radiofrequency signal, 
which avoids the magnetic field and only the effect of electric field contribution was evaluated.  
Impedance meter resonator (HP 4192A LF Impedence Analyzer, Figure 5.5) permitted to pick up 
the modulus and the phase of the impedance to the current with respect to the voltage in the 
range of frequency 1 kHz to 10 MHz.  
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Figure 5.5: Impedance Analyzer 
The samples used for this measurement had a disk cylindrical shape with 300 m as a thickness 
and a diameter of 68 mm. Each sample was then placed into the position of maximum electric 
field in contact with two cylindrical copper plates in order to create a capacitor.  
It was possible to measure the capacity of a dielectric with the effect of the frequency. This 
parameter characterizes the capacitor since it depends only on the geometry of the component 
and the characteristics of the dielectric interposed between the two armatures. 
The measure of reactance Xc in presence of purely capacitive impedance was performed:  
CX
C

1
  with ω = 2 π f (5.1.10) 
Taking into account that the capacity of a plane capacitor with parallel faces is: 
d
A
C r 0  (5.1.11) 
It was possible to calculate the dielectric permittivity r  knowing all other parameter.  
5.1.11.2. Magnetic permittivity measurements  
This measurement involved the creation of a cylinder, with a d= 6 mm and height 8.5 mm, around 
which a copper coil with 100 windings was wrapped. In this case there is only the response of the 
magnetic field in the material which is expressed by the evaluation of the inductance L. 
With the impedance meter the modulus and phase of the current with respect to the voltage were 
measured and the imaginary component of the impedance Z was calculated. 

LXL   with ω = 2π f    (5.1.13) 
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It gained magnetic permittivity µ, knowing all the other parameters.  
l
AN
L
2
       (5.1.14) 
Where : 
N number of coils 
A section of magnetic nucleus 
l length of the nucleus around the coils 
µ magnetic permittivity [10] 
The goal of this test was the evaluation of the dielectric and magnetic permittivity in order to 
investigate if and how the magnetic glass ceramic influenced the polymer responses.  
5.1.12. Mechanical tests 
Mechanical characterization permitted to test the load-bearing ability of the composite material. 
For the polymeric bone cement both compression and four point bending tests were performed. 
In table 5.2 the values of compressive strength, the limits of bending strength and elastic modulus 
that the material must respect are reported.  
 
Table 5.2: Inferior limit of applicability of bone cement in compression and bending [9] 
The compression and the bending tests were performed with a growing static stress applied up to 
the sample failure. In the compression test the sample was subjected to deformation under 
uniaxial compression stress at a constant speed measuring the load (variable independent) 
necessary to provide a given compression (variable dependent). 
Composites bone cements (P10, P15 and P20) and commercial composition were subjected to 
mechanical compression and bending test in accordance with ISO 5833 [11]. For both tests five 
specimens were prepared with dimensions required by the standards: cylindrical samples with, 
6x12 mm, for the compression test and rectangular specimens, 75x10x3,3 mm, for the bending 
test. Before testing, the planarity of each sample surface was checked. Then, they were tested for 
the evaluation of the maximum compression strength. Compression strength was detected using a 
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Sintech 10/D (MTS) machine in figure 5.6, with a constant cross-head speed of 20 mm/min and a 
load cell of ±5 kN. The samples were prepared 24 hours before the test and they were stored at 
room temperature. 
 
Figure 5.6 : Compression machine  
 
Figure 5.7: ideal compression test, following the application of a force the hight of the sample change from lo from l with a 
deformation of the specimen. 
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Figure 5.8 Theoretical load-displacement diagram for a cement 
For each cylinder the offset load (point 2 in figure 5.8) was recorded and the value of the 
compressive strength was expressed in Megapascals (MPa) by dividing this force by the original 
cross-section area, in square millimetres, of the cylindrical sample. The average compressive 
strength of the five cylinders was calculated. 
Bending strength and modulus were evaluated using a test machine H25KS with a load cell of ± 
5kN produced by Tinius Olsen Ltd. In four points bending test the moving crosshead pushed two 
wedges arranged symmetrically to the centre line of the specimen. During the test the 
displacement of the crosshead and the applied load were measured [12]. 
Figure 5.9 reports a diagram of the flexural momentum during the test, demonstrating that the 
bending moment remains constant between the two supports. 
 
Figure 5.9: Distribution of bending moment in a  4 point flexural test  
 
The bending strength and bending modulus were evaluated respectively according the formula: 
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 (5.1.21) 
Where 
F= force at break in Newton 
a = distance between the inner and outer loading points (20 mm) 
b = average measured width of specimen, in millimeters 
h = average measured thickness of specimen, in millimeters; 
 
(5.1.15) 
Where 
F = force at break, in newton; 
a = distance between the inner and outer loading points (20 mm ) 
f = difference between the deflections under the loads of 15 N and 50 N , in millimeters; 
b = average measured width of specimen, in millimeters 
h = average measured thickness of specimen, in millimeters; 
l = distance between the outer loading points ( 60 mm);[11] 
The fracture surfaces of samples after bending test were analyzed by SEM; three samples for each 
cement composition were observed: sample broken at σ maximum, σ medium and σ minimum. 
5.1.13. Setting time tests 
The setting time was investigated in accordance with ISO 5833-2002. All three composite cement 
formulations were evaluated. 
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Figure 5.10: Typical setting time curve of polymeric bone cement[11]  
 
Figure 5.11: Experimental set up for setting time test in according with ISO 5822- 2008. 
The powder and the liquid monomer were mixed together in a bowl. After the liquid wetted all the 
powder the paste was put in a teflon mould, in conformity to the standard specification (see figure 
5.11b), it was covered and a temperature probe was insert and put in contact with the cement 
during the polymerization reaction in order to collect time/temperate data. The used temperate 
probe was a digital thermocouple datalogger by Tersid.  
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5.1.14. Micro Computed Tomography (MicroCT) 
Micro computed tomography (micro-CT) is a non-destructive technique that can produce 3D sets 
of images. Micro-CT analyses were performed with a SkyScan1174®, using a 50 kV–800 mA x-ray 
source and a camera pixel size of 13,42 mm. The exposure time was 5,2 s per projection. The 
images were recorded on a 1024x1304 CCD detector, with the pixel size set to 6,5 mm. A 330 mm 
Al filter was used. The 3D structure was reconstructed by means of the Nrecon® software and for 
the 3D visualization of the reconstructed sample, the CTVox® software was used. For each sample 
a volume of interest was built; and a single voxel of reconstructed image had a size of 6,5x6,5x6,5 
μm. The micro-CT analysis was carried out to evaluate the porosity of the composite cements and 
the dispersion of the glass ceramic in the polymeric matrix.  
5.1.15. Composite bone cement: in vitro tests 
5.1.15.1. Bioactivity tests 
In order to evaluate the composite bioactivity, in vitro test by soaking samples in Simulated Body 
Fluid (SBF, Kokubo Protocol [17]) was performed. The bioactivity of glasses is based on their ability 
to induce the in vitro formation of a semi crystalline hydroxyapatite (HAp) rich layer through a 
sequence of ion exchange steps. This behavior is considered as an indication of their in vivo 
bioactivity (i.e. their bonding ability to living tissues). 
The SC45 is a glass-ceramic that presents bioactive activity [3] but with a slow kinetic. 
Nevertheless, after one month of soaking in a simulated body fluid (SBF)(see the chemical 
composition in figure 5.12) a thin silica gel layer can observed on its surface together with some 
precipitates of a phase rich in calcium and phosphorous [4]. This glass-ceramic was already tested 
in a previous work for its biocompatibility showing a high degree of cytocompatibility [4].  
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Figure 5.12: SBF composition in comparison of human plasma[17] 
Each composite cement (P10, P15, P20) was soaked in 25 ml of SBF and maintained at 37°C for 
four weeks. Every three days the solution was refreshed and the value of the pH was measured. 
At the end of the treatment, samples were gently washed in distilled water, dried at room 
temperature and characterized by morphological and compositional analyses by Scanning Electron 
Microscopy (SEM– FEI, QUANTA INSPECT 200) and Energy Dispersion Spectrometry (EDS - EDAX PV 
9900). 
5.1.15.2. Leaching test 
Composites bone cements were subjected to leaching test in order to assess if any iron release 
could occur, causing a potential risk of iron overloading in the fluids in future in vivo applications. 
The leaching of other ions, involved in the bioactivity mechanism, was not the object of the 
present work. The cement formulation containing the highest SC 45 amount (P20) was selected for 
the test in order to evaluate the maximum value of potential leaching. The samples were dipped in 
30 ml of SBF, at 37°C, up to one month.   
At determined time steps (3h, 1, 3, 7, 14 and 33 days) an aliquot of the solution was picked out 
and analyzed, after mineralization with nitric acid (for trace analyses, 69% w/w) and dilution with 
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milliQ water, by Graphite Furnace Atomic Absorption Spectrometer (GF-AAS 4100 ZL, Perkin 
Elmer, autosampler AS/71, Zeeman Effect background correction). The calibration curve was 
performed diluting a mother solution of iron in nitric acid (1g/L) in milliQ water (final 
concentrations: 5, 10, 25, 50 g/l). Accuracy was determined analysing the NIST standard SRM 
1643e - Trace Elements in Water. 
The test was performed in triplicate and commercial cements containing 20%wt of Bioglass® 
(without Fe in any form) was selected as control samples. 
5.1.15.3.  Cytocompatibility tests 
Tests were performed at University of Piemonte Orientale "A.Avogadro" with the collaboration of 
Prof.ssa Lia Rimondini and Dr. Andrea Cochis. 
5.1.15.4.  Cells cultivation 
Human osteosarcoma cells (ATCC CRL-1427, Mg63) were cultivated in Dulbecco’s Modification 
Minimal Essential Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum (FBS, 
Sigma) and 1% antibiotics (penicillin – streptomycin) at 37°C, 5% CO2. Cells were cultivated until 
80-90% confluent, detached with a trypsin-EDTA solution and used for experiments. Mg63 cells 
were used as representative for osteoblasts cells since the composite cements are intended for 
osteointegration. This cell line is commonly used to investigate the cytocompatibility of 
biomaterials for bone substitutions for preliminary in vitro studies. 
5.1.15.5. Indirect  Cytocompatibility test 
For the indirect test, serum free DMEM was incubated without cells for 1 week at 37°C, 5% CO2 in 
direct contact with controls, Palamed®, test samples (P10, P15 and P20). Afterwards, eluates were 
collected, supplemented with 10% FBS and used to cultivate Mg63. Cells were seeded in a defined 
number (1x104 / well) into 24 wells plates (Cell Star, PBI International) and cultivated for 24, 48 
and 72 hours at 37°C, 5% CO2. Afterwards, cells viability was evaluated by the (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric assay (MTT, Sigma). Briefly, 50 
l of MTT solution (3mg/ml in phosphate buffered saline (PBS), ph 7.4) were added to each sample 
and incubated 4 hours in the dark; afterwards, formazan crystals were solved with 100l of 
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dimethyl sulphoxyde (DMSO, Sigma) and 50 l were collected and centrifuged to remove 
eventually debris. Surnatant optical density (o.d.) was evaluated at 570nm with a 
spectrophotometer (Spectra Count, Packard Bell). Polystyrene samples o.d. were used as control 
and considered as 100% cells viability while coated samples viability was calculated as follow: 
(sample o.d. / control o.d.) *100 . Experiments were performed in triplicate for controls and test 
samples. Furthermore, cells morphology was visually investigated after 24, 48 and 72 hours of 
cultivation by light microscope (Leica AF 6500, Leica Microsystems). 
5.1.15.6. Direct Contact Cytocompatibility evaluation 
For the direct contact assay, cells were seeded in a defined number (1x104 / sample) directly onto 
the surfaces of each samples and cultivated in DMEM 10% FBS at 37°C, 5% CO2. Cells viability was 
evaluated after 24, 48 and 72 hours with the MTT assay as described in the indirect assay section. 
Experiments were performed in triplicate. 
5.1.15.7. Morphological Evaluation  
The morphology of cells attached to the samples surfaces was investigated also by FESEM 
microscopy (FESEM - SUPRATM 40, Zeiss) equipped with Energy Dispersive Spectroscopy (EDS). 
Briefly, samples were removed from the media, gently washed with PBS, fixed with 2.5% 
glutharaldehyde for 2 h in 1 mol L21 sodium cacodylate buffer, washed with the latter, dehydrated 
with 70%, 80%, 90%, and 100% ethanol (10 min each), and finally treated with CO2 at top critical 
point. Specimens were fixed on aluminum stubs using a conductive silver paste, covered with a 
chromium layer, and visualized at various magnifications. 
5.1.16. Statistical analysis of data 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS v20.0, IBM 
Co. Armonk, New York, US). The assumptions of homogeneity of variances and normal distribution 
of errors were checked for all the variables considered: afterwards, ANOVA one-way and post-hoc 
Sheffe’s test were used. The significance level was set at 5%. 
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5.1.17. Hyperthermia on tumor cells  test 
On the basis of data incoming from previous test, a simplified simulation of an hyperthermia 
application on a culture of tumor cell was performed. 
5.1.17.1.  Culture Cells Preparation  
The test was performed as a comparison between P10 and control PMMA . Two different types of 
cells have been used: 
1. HFOB: fetal human osteoblast cells, non tumoral, non-tumorigenic. 
2. Mg63: human osteoblast from osteosarcoma, tumoral and tumorigenic  
Cells were cultivated in Dulbecco’s Modified Eagle Medium (Mg63, DMEM, Sigma) or Ham’s F12 
mixture 0,05 mg/ml G418 salt (HFOB, Sigma) supplemented with 10% fetal bovine serum (FBS, 
heat-inactivated, Sigma) and 1% antibiotics (penicillin- streptomycin, Sigma). Cells were cultivated 
until 80-90 % confluence , detached with trypsin-EDTA solution (0,05% in PBS, Sigma) and used for 
experiments.  
5.1.17.2. Cytocompatibility evaluation  
Round 0,5 cm diameter 8mm thickness P10 and Palamed specimens were sterilized by 70% 
ethanol immersion overnight prior to use with cells. Afterwards, specimens were placed into the 
wells of a 24 multi-well plate (CellStar, PBI International , Milan , Italy) and cells (Mg63 and HFOB ) 
were seeded in a defined number (2x105 cells/ sample, 1 ml/sample) directly onto specimens 
surfaces; plate was incubated 48 hours at 37°C , 5% CO2 in a humid atmosphere. Then, cells 
viability was evaluated by the colorimetric metabolic assay (3-(4,5-dimethylthiazol-2-yl)-
2,5diphenyltetrazolium bromide, (MTT, Sigma). Briefly, 100 µl of MTT solution (3 MG/ML IN pbs) 
were spotted into each well; plates were incubated for 4 hours in the dark in a 37°C incubator. 
Afterwards, medium was removed and formazan crystals formed on the specimens surface were 
solved with 100 µl of DMSO. Finally, 50 µl were collected from each well, centrifuged in order to 
remove eventually debris (12000 rpm, 1 minute) and the optical density was evaluated by a 
spectrometer (Spectra Count , Packard Bell, Chicago, USA) at a 570 nm wavelength. 
Experiments were performed in triplicate and results were expressed as means and standard 
deviations.  
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5.1.17.3. Hyperthermic treatment  
Specimens prepared as a previously described in the cytocompatibility assay (2x105 cells/ sample, 
48 hours cultivation) were treated with a magnetic inductor (Egma 6 produced by FELMI S.r.l.) . 
The machine was set with a magnetic field of 22,5 mT with a fixed working frequency of 220 kHz. 
Specimens (Palamed and P10) were treated for 5-10-15-20-30 minutes under alternate magnetic 
field. For each time, three samples with tumoral (Mg63) cells and three with non tumoral 
(Hfob)cells were tested with the magnetic field generator. Then, cells viability was evaluated by 
MTT test as previously described. Non- treated samples were considered as control and their 
optical density (o.d.) considered as 100% ; tested samples o.d. was expressed as cells viability 
percentage as a function of controls. Experiments were performed in triplicate and results 
presented as means and standard deviations. 
5.1.17.4.  Cells morphology evaluation  
After each assay (cytocompatibility and hyperthermic evaluations), cells morphology was visually 
checked by scanning electron microscopy (FESEM). Briefly , samples seeded with cells were fixed 
20 minutes at room temperature with 2.5 % glutharaldehyde (Sigma , in PBS); then samples were 
gently washed with PBS and dehydratated with alcohol scale (70-90-100%, 10 minutes each). 
Finally samples were treated with hexamethyldisilazane (Sigma, 2 minutes), covered with a thin 
layer of chromium for 1 minute, put on a dedicated SEM stubs and observed with the instrument 
at various magnifications. 
5.1.17.5. Hyperthermic treatment apoptosis induction   
After hyperthermic treatment application, cells apoptotic induction was evaluated by Annexin-5 
staining (Fitch-conjugated Annexin-5 , ImmunoTools, Germany). Cells on specimens treated 
surface were fixed with formaldehyde (3,7% in PBS) 20 minutes at room temperature. Then 
samples were gently washed with PBS and Annexin-F was added (1:200 in a 5% goat serum 1% 
bovine albumin in a PBS solution ) at room temperature. Afterwards, cells were carefully washed 
three times (5 minutes each) with PBS and permeabilized 5 minutes with Triton (0,25% in PBS). 
The DAPI ( 1:250 in PBS, Sigma) was used to counter staining cells nuclei. Samples were observed 
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under a fluorescent microscope (Leica) and the Annexin-5 positive cells counted. Results were 
expressed as % of Annexin-5 positive cells towards the cells total number. 
Experiment were performed in triplicate and expressed as mean and standard deviations.  
5.1.17.6. Heating up to a target temperature 
The effectiveness of hyperthermia treatment is closely related to the temperature that can be 
reached in the tumor tissue closed to bone cement insert (i.e = thermal power generator ) and to 
maintain it for the whole required time of treatment (40-43 °C ). 
In order to characterize the treatment efficacy, the Cumulative Equivalent Minutes at 43°C (CEM43) 
was calculated, using the equation derived by Stephen and Dewey [20] as a clinical means to 
estimate the actual thermal dose: 
CEM43 = Σ R(43-T)Δt 
where:  
R=0.5 for T>43°C  
R=0.25 for 39°C<T<43°C  
R=0 for T<39°C 
In the foreseen applications in human body it will be difficult to control the local temperature in 
the treated volume because infrared-camera measures are applicable only on visible surfaces and 
metallic thermocouples are affected by the variable magnetic field. 
For these reasons, it was necessary to perform a thermal study aimed to define the parameters of 
treatment. The Element Finite method allowed a good simulation of power generation. The heat 
was transferred by conduction and convection and it was applied to the section test used to 
simulate a hyperthermia treatment on tumoral cells 
Using a geometry produced with Comsol Multiphysics ® (Comsol Inc.) it was outlined the 
experimental model which consists of a cement bone cylindrical sample ( diameter 10 mm , height 
5 mm ) placed at the centre of a large sample holder (inner diameter 30 mm , height 10 mm, 
thickness 3 mm ) filled by water up to 1 mm above the sample surface . 
In this geometry a sufficiently fine mesh was created automatically by the software, taking into 
account different materials and heat transfer condition (figure 5.13 ). 
